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ABSTRACT 
Cardiovascular disease is responsible for the loss of one life every 38 
seconds and accounts for 26.6 percent of all infants that die of congenital birth 
defects.  Adrenergic hormones are critically important regulators of 
cardiovascular physiology in embryos and adults.  They are key mediators of 
stress responses and have profound stimulatory effects on cardiovascular 
function, and dysregulation of adrenergic function has been associated with 
many adverse cardiac conditions, including congenital malformations, 
arrhythmias, ischemic heart disease, heart failure, and sudden cardiac death.  
Despite intensive study, the specific roles these hormones play in the developing 
heart is not well-understood.  Further, there is little information available 
regarding how these important hormones mediate stress responses in adult 
females (before and after menopause) in comparison to males.  My thesis thus 
has two major foci:  (1) What role(s) do catecholamines play in the embryonic 
heart?, and (2)  Do catecholamines differentially influence cardiac function in 
aging male and female hearts? 
Initially, we sought to uncover the roles of adrenergic hormones in the 
embryonic heart by utilizing an adrenergic-deficient (Dbh-/-) mouse model.  We 
found that adrenergic hormones influence heart development by stimulating 
expression of the gap junction protein, connexin 43, facilitating atrioventricular 
conduction, and helping to maintain cardiac rhythm.  As development 
progresses, cardiac energy demands increase substantially, and oxidative 
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phosphorylation becomes vital.  Adrenergic hormones regulate metabolism in 
adults, thus we hypothesized they may stimulate energy metabolism during the 
embryonic/fetal transition period.  We examined ATP, ADP, oxygen consumption 
rate, and extracellular acidification rates and found these metabolic indices were 
significantly decreased in Dbh-/- hearts compared to Dbh+/+ controls.  We 
employed transmission electron microscopy of embryonic cardiomyocytes and 
found the mitochondria were significantly larger in Dbh-/- hearts compared to 
controls, and had more branch points.  Taken together, these results suggest 
adrenergic hormones play a major role mediating the shift from predominantly 
anaerobic to aerobic metabolism during the embryonic/fetal transition period. 
 Since there are known differential cardiac responses due to sex, age, and 
menopause to stress, we used echocardiography to measure left ventricular (LV) 
function in adult (9, 18 and 21 month) male and female mice (pre and 
postmenopausal) in response to epinephrine, and immobilization stress to 
investigate the roles of these factors.  My results show 9-month premenopausal 
female mice display significantly decreased LV responsiveness to epinephrine 
compared to males, and an increased response to epinephrine due to age, 
especially in the premenopausal females.  Similar LV function was also observed 
between postmenopausal females and males, and this pattern persisted after 
immobilization stress.  I also investigated anatomical differences in the 
distribution of adrenergic cells within the heart comparing age, sex, and 
menopausal status.  Notably, the density of cells derived from an adrenergic 
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lineage in the heart was significantly increased in postmenopausal mice 
compared to age-matched males and cycling females.  The selective re-
appearance of adrenergic cells in the heart following menopause may provide an 
explanation for the differential stress responses observed in our system, and 
could have important clinical ramifications for stress-induced cardiomyopathies. 
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CHAPTER ONE: INTRODUCTION 
Adrenergic hormones and embryonic electrophysiology 
The mammalian cardiac conduction system is comprised of the SA and 
AV nodes, bundle of His, and Purkinje fibers (Christoffels and Moorman, 2009; 
Moorman et al., 1998).  The electrical signal is propagated in the SAN and 
travels to the AVN where there is a significant delay.  The signal then travels to 
the bundle of His, located in the interventricular septum, where it is then passed 
to the interventricular Purkinje fibers to initiate ventricular muscular contractions 
(Keith and Flack, 1907). 
The mouse primitive embryonic heart begins to display contractions at 
approximately embryonic (E)7.5 (~22 days in humans).  This is considerably 
earlier than sympathetic innervation of the heart is seen, E16-17 in rat 
(Shigenobu et al., 1988).  The adrenergic hormone synthesizing enzyme 
phenylethanolamine-n-methyltransferase (PNMT) (Figure 1), however, was found 
to be present as early as E9.5 in the rat heart (~E8.5 in mouse) (Ebert et al., 
1996).  Similar findings of this and other catecholamine biosynthesis enzymes 
(ie. tyrosine hydroxylase and dopamine β-hydroxylase) have been shown in the 
chick and even human heart (Huang et al., 1996; Ignarro and Shideman, 1968a, 
b). 
The localization of these “Intrinsic Cardiac Adrenergic” (ICA) cells is 
intriguing as they are found to colocalize with regions of the AV canal and the 
dorsal venous valve cusp at rat E11.5 (Ebert et al., 1996).  These regions of the 
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embryonic heart further develop into the AV node and SA node, respectively 
(Viragh and Challice, 1977, 1980, 1982).  These cells are seemingly transitory 
and later at E16.5 (rat) large clusters where observed in the crest of the 
interventricular septum, the sight of the bundle of His and Purkinje fibers (Ebert 
et al., 1996).  In addition, at E15.5 (mouse) co-staining was observed between 
historical staining of adrenergic cells and Hyperpolarization-activated cyclic 
nucleotide-modulated channel isoform 4 (HCN4) (Ebert et al., 2004) a protein 
associated with pacemaker properties found in the SA node (Stieber et al., 
2003). 
While there is strong evidence for colocalization of ICA cells with key 
pacemaker and conduction regions of the heart few studies have investigated the 
relationship between adrenergic hormones and the electrophysiology of the 
embryonic heart and the necessity of these hormones for proper function of the 
conduction system.  Here we explore the roles of adrenergic hormones in the 
development of the embryonic conduction system. 
Adrenergic hormones and embryonic energy metabolism 
The primary source of adenosine triphosphate (ATP) during fetal 
development is commonly reported to be from glycolysis and lactate production, 
with a ‘fetal-shift’ occurring at birth where the primary source of ATP production 
‘shifts’ to oxidative phosphorylation in the mitochondria (Duncan, 2011; Madrazo 
and Kelly, 2008; Makinde et al., 1998).  A typical example of this notion from the 
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literature is stated as follows (Duncan, 2011; Madrazo and Kelly, 2008): 
‘…metabolic programming often is referred to as a ‘fetal’ shift because the 
myocardium of the developing embryo relies mostly on glycolysis and lactate 
metabolism for its ATP production’.  It has been known for more than 40 years, 
however, that mammalian hearts show an increase in the importance of oxidative 
phosphorylation for ATP production during the embryonic development (Cox and 
Gunberg, 1972; Ellington, 1987; Shepard et al., 1970).  Additionally, there is 
accumulating evidence from targeted genetic studies in mice showing embryonic 
lethality due to disruption of genes associated with the mitochondria and/or 
dysfunctional oxidative phosphorylation.  Moreover, cardiovascular development 
has been well studied using transgenic mice demonstrating embryonic lethality 
occurring around the time of mitochondrial maturation during organogenesis 
(Conway et al., 2003; Porter et al., 2011).  Organogenesis begins around 
embryonic day 8.0 (E8.0) in mice, which is equivalent to about day 17–19 
(Carnegie Stage 8) in humans (O'Rahilly, 1979; Theiler, 1972).  
Interestingly, this is approximately the stage of development when 
increased embryonic lethality due to the genetic disruption of mitochondrial 
associated genes occurs (Figure 2) thereby demonstrating that embryonic 
mitochondrial function is indeed critical for embryonic and fetal development in 
utero.  In support of this genetic evidence, electron microscopy has shown an 
obvious maturation of mitochondria and cristae development between E10–12 in 
rat embryos (equivalent to E9.0–E10.0 in mice) (Shepard et al., 1998).  Further, 
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the inhibition of glycolysis using the drug 2-deoxyglucose did not show a 
decrease in E9.0 mouse ATP concentrations, indicating an alternative 
mechanism of energy production (e.g. oxidative phosphorylation) (Hunter and 
Tugman, 1995).  Until recently, the study of oxidative phosphorylation and 
mitochondrial maturation in utero had not been thoroughly investigated, but a 
new mechanism for the induction of mitochondrial maturation was proposed 
involving the closure of the mitochondrial permeability transition pore (mPTP) 
beginning at E9.5 in mouse cardiomyocytes (Hom et al., 2011).  The closure of 
the mPTP led to increased oxidative phosphorylation and decreased ROS 
production in the E9.5 mouse heart, and has thus been proposed as a key 
mechanism in the maturation of mitochondrial function in the developing embryo 
at a time when the embryo becomes dependent on aerobic metabolism (Hom et 
al., 2011). 
Here, my studies show a link between adrenergic-hormones and 
mitochondrial functional maturation during embryogenesis.  Adrenergic 
stimulation is known to regulate metabolism in adult organs, including the heart 
and liver, however, this is the first study to carefully examine adrenergic 
regulation of embryonic energy metabolism in the developing embryonic heart.   
Adrenergic hormones, stress, age and gender 
The impacts of emotional stress on health have been generally recognized 
since ancient times, but only in relatively recent years have scientists and 
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clinicians started to gain an understanding of the pathophysiological mechanisms 
linking emotional stress to specific dysfunctions within the cardiovascular system. 
In contrast, biological manifestations of physical stress are much more 
extensively characterized, and broadly include hypertension, ischemic heart 
disease (including myocardial infarction and its consequences), myocarditis, 
cardiomyopathies, heart failure, arrhythmias, and sudden cardiac death (Steptoe 
and Kivimaki, 2012).  While emotional stress may also contribute to these 
conditions, the specific pathophysiologic manifestations of emotional stress are 
only beginning to emerge. 
Takotsubo Syndrome is a prototypical stress-induced cardiomyopathy. 
The first clinical cases of this stress cardiomyopathy were reported in Japan in 
1990 (H. Sato, 1990). Early reports described a transient hypokinesis or akinesis 
in the apex of the LV in patients suffering from acute emotional stress (Bybee 
and Prasad, 2008; Hurst et al., 2010; Tsuchihashi et al., 2001).  The unusual 
shape of the heart in these patients bore a striking resemblance to a Japanese 
octopus trap, and hence, it was named “takotsubo”, meaning octopus trap in 
Japanese (Dote et al., 1991; H. Sato, 1990; Tsuchihashi et al., 2001).  Takotsubo 
Syndrome is also referred to as “Broken Heart Syndrome” (due to the emotional 
stress connection), “Ampulla Cardiomyopathy” (due to the peculiar shape of the 
heart), or “Apical Ballooning Syndrome” (to describe one of the most pronounced 
clinical features commonly observed in these patients) (Hurst et al., 2010).  
Takotsubo Syndrome is also referred to as a “Stress-Induced Cardiomyopathy” 
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or more simply, “Stress Cardiomyopathy”.  These terms have become essentially 
interchangeable when describing this syndrome (Sharkey et al., 2011).  For this 
purpose, we will use the historical “Takotsubo Cardiomyopathy (TTC)” 
designation as the prototype clinical form of stress-induced cardiomyopathies.  It 
is important to note, however, that stress induction for TTC need not be 
exclusively emotional or psychological, but can also be precipitated by physical 
stressors such as pharmacological challenge with adrenaline and other 
adrenergic agonists (Abraham et al., 2009; Litvinov et al., 2009), complications 
from other diseases (e.g., pheochromocytoma) (Marcovitz et al., 2010; Naderi et 
al., 2012), physical trauma from injury or surgery, and a wide variety of other 
physical stressors (Ennezat et al., 2005; Patel et al., 2013). 
The common feature of both physical and psychological stress responses 
in these contexts is elevated plasma catecholamines (Akashi et al., 2004; Ito et 
al., 2003; Kume et al., 2008; Wittstein et al., 2005).  Indeed, studies examining 
plasma catecholamine concentrations in TTC patients have shown high levels of 
circulating catecholamines compared to those from control groups (Shao et al., 
2013a; Wittstein et al., 2005).  The fact that exogenously administered 
catecholamines can induce TTC-like symptoms in patients and animal models 
further supports adrenergic mediation of this syndrome (Abraham et al., 2009; 
Izumi et al., 2009; Shao et al., 2013a; Shao et al., 2013b).  TTC symptoms have 
also been reported in some patients with pheochromocytoma, which results in 
abnormally high concentrations of circulating endogenous catecholamines 
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secreted from adrenal medullary tumors (Kim et al., 2010).  TTC symptoms have 
responded favorably to pharmacological intervention with beta-blockers in some 
cases (Bybee and Prasad, 2008).  Taken together, these observations strongly 
implicate the major peripheral catecholamines, adrenaline and noradrenaline, as 
key players in acute precipitation of TTC. 
We hypothesize the pathogenesis of TTC is due (in part) to a local release 
of catecholamines that overload adrenergic receptor signaling systems in specific 
regions of the heart (Kume et al., 2008; Osuala et al., 2011), however the other 
prevailing hypothesis include coronary microspasms and increased β-adrenergic 
receptor densities (Figure 3).  During stress, there is input from sympathetic 
nerves as well as circulating catecholamines, but there are also 
autocrine/paracrine actions of catecholamines from stores within the heart itself 
(Armour et al., 1997; Ebert et al., 1996; Ebert and Taylor, 2006; Ebert and 
Thompson, 2001; Elayan et al., 1990; Huang et al., 1996; Osuala et al., 2011; 
Papka, 1974).  As mentioned earlier, sympathetic nerve input is not uniform 
throughout the LV. There is much greater nerve terminal density in the base 
compared to mid or apical sections of the LV (Angelakos, 1965; Pierpont et al., 
1984).  Kume et al, 2008 measured catecholamines from two locations 
representing base (aortic root, Ao) and apex (coronary sinus, CS) in five 
confirmed cases of TTC.  In all five cases, concentrations of noradrenaline and 
dopamine were elevated in CS compared to Ao, whereas adrenaline 
concentrations were unchanged or slightly decreased.  These results suggested 
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there may indeed be differential local catecholamine concentrations in apical and 
basal regions of the left ventricular myocardium.  
Another piece of evidence comes from recent studies in the mouse heart 
showing cells marked by expression of the adrenaline biosynthetic enzyme, 
phenylethanolamine n-methyltransferase (Pnmt), were found to be concentrated 
on the left side of the adult heart (Osuala et al., 2011).  More specifically, Pnmt+ 
cells were localized to swaths or finger-like projections into left ventricular 
myocardium at the apex, mid, and basal regions (Osuala et al., 2011).  These 
data suggest there may be an anatomical substrate for regional catecholamine 
production differences in the heart.  Nearly 90% of Pnmt-derived cells were found 
to be localized to the left side of the heart, which could, in theory, help to explain 
why left ventricular function is selectively influenced in TTC.  Moreover, the 
regional variations within the LV could likewise help to explain how those areas 
could be susceptible to local surges in catecholamines.  It is also possible that 
local presence of catecholamines in these regions during development may 
influence the expression and functional sensitivities of adrenergic receptor 
subtype distributions in the LV.  Although this has not been explicitly 
demonstrated in the heart, there are numerous studies showing that innervation 
and adrenergic receptor expression is influenced by catecholamine exposure 
(Clarke et al., 2010; Habecker et al., 1996; Lau et al., 1982). 
Notably, many of the Pnmt-derived cells in the adult mouse heart appear 
to be myocytes, though neuronal-like and immature embryonic-like Pnmt-derived 
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cells were also identified in these regions (Osuala et al., 2011).  Clear examples 
of striated myocardial cells marked with XGAL to denote Pnmt expression were 
observed in the LV (Ebert et al., 2008; Osuala et al., 2011).  These results 
suggest there may be autocrine or paracrine actions of local catecholamines 
from non-neuronal as well as neuronal sources.  This idea is not new (Kimura et 
al., 2012; Kloberg and Fritsche, 2002; Slavikova et al., 2003), but is often 
overlooked in modern studies and textbooks.  The classic work of Spurgeon et al. 
(Spurgeon et al., 1974) showed that cardiac adrenaline concentrations remain 
relatively high in the heart following surgical and chemical (6-hydroxydopamine, 
6-OHDA) denervation, while noradrenaline concentrations were nearly 
completely eradicated by these procedures.  The authors concluded that cardiac 
noradrenaline content was mostly neuronal while only ~50% of the adrenaline 
content was neuronal.  They hypothesized that cardiac adrenaline “is held in non-
neuronal stores either in chromaffin cells, in the specialized cells themselves or 
in cardiac analogs of chromaffin cells” (Spurgeon et al., 1974).  There is ample 
evidence for these from a wide variety of species (Abrahamsson et al., 1979; 
Ellison and Hibbs, 1974; Forsgren et al., 1990; Padbury et al., 1981), including 
humans (Dail and Palmer, 1973), suggesting their presence is highly conserved 
and, therefore, likely critical for survival.  It remains to be determined if these 
cells truly play a significant role in TTC, but they certainly represent a potential 
local source of adrenaline that could contribute to regional variations in 
adrenergic stimulation within the LV.  
10 
 
 To investigate this further I performed longitudinal high-resolution 
echocardiography on male and female mice ranging from 9 to 21 months old. 
Additionally, to test if menopausal status affects left ventricular heart function 
ovarian follicle failure was induced and echocardiographs were repeated.  The 
effect of stress on heart function was tested by the injection of epinephrine and 
immobilization.  Lastly, adrenergic cell distributions patterns within the heart were 
determined using X-gal staining. 
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Figures 
 
 
 
 
Figure 1 Catecholamine biosynthetic pathway 
Catecholamine biosynthetic pathway with enzymes next to arrows. 
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Figure 2 Timeline of attrition in genetic knock-out models that affect 
mitochondrial function  
‘ X’ represents a model of mitochondrial-associated lethality; vertical dashed lines 
indicate timing of ‘embryonic-shift’ from anaerobic to aerobic metabolism. Please 
note that arrows depicting timelines of activity for ‘glycolysis’ and ‘oxidative 
phosphorylation’ are qualitative and mainly serve to indicate the relative 
importance of glycolysis (and subsequent lactic acid formation through anaerobic 
means) and oxidative phosphorylation in mitochondria for proper embryonic and 
foetal development.   
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Figure 3 Schematic illustrations of three distinctive models proposed to 
explain TTC mechanisms.  
1. Coronary Microspasms:  In this model, stress-induced surges in 
catecholamines trigger coronary microspasms, which then lead to decreased 
blood flow and regional myocardial inactivity. 2. Increased β2-Receptor Density: 
This model proposes that β2-adrenergic receptors are more concentrated at the 
apex compared to the base.  High concentrations of adrenaline cause these 
receptors to switch from Gs to Gi, which results in myocardial stunning in affected 
regions that would appear as akinetic or hypokinetic sections of LV during 
systole. 3. Increased Local Catecholamine Release: In this hypothesis, 
adrenaline and/or noradrenaline are released locally in the apex, mid, and/or 
basal regions of the LV from non-neuronal resident adrenergic cell populations 
(depicted by the highlighted blue areas). This local release overstimulates 
adrenergic receptors that are already near saturation from circulating adrenaline 
and sympathetic nerves (NA). Abbreviations:  HPA, Hypothalamic-Pituitary-
Adrenal (axis); A, adrenaline; NA, noradrenaline 
  
1 3 2 Coronary Microspasms Increased β2 Receptor Density Increased Locally Released 
Catecholamines 
EPI 
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CHAPTER TWO:  
ADRENERGIC DEFICIENCY LEADS TO IMPAIRED ELECTRICAL 
CONDUCTION AND INCREASED ARRHYTHMIC POTENTIAL IN 
THE EMBRYONIC MOUSE HEART 
Abstract 
The adrenergic hormones, epinephrine and norepinephrine, are produced 
by cardiac cells in the pacemaking and conduction system, as well as other 
portions of the heart during a critical period of embryonic development when 
adrenergic action is essential for survival.  The underlying mechanisms of 
adrenergic action in the embryonic heart, however, are not well-understood.  To 
determine if adrenergic hormones play a critical role in the functional 
development of the cardiac pacemaking and conduction system, we employed a 
mouse model where adrenergic hormone production was blocked due to targeted 
disruption of the dopamine -hydroxylase (Dbh) gene.  Immunofluorescent 
histochemical evaluation of the major gap junction protein, connexin 43, revealed 
that its expression was substantially decreased in adrenergic-deficient (Dbh-/-) 
mouse hearts relative to adrenergic-competent (Dbh+/+ and Dbh+/-) at embryonic 
day 10.5 (E10.5), whereas pacemaker and structural protein staining appeared 
similar.  To evaluate cardiac electrical conduction in these hearts, we cultured 
them on microelectrode arrays (8x8, 200 µm apart).  Our results show a 
significant slowing of atrioventricular conduction in adrenergic-deficient hearts 
compared to controls (31.4 ± 6.4 vs. 15.4 ± 1.7 ms, respectively, p < 0.05).  To 
determine if the absence of adrenergic hormones affected heart rate and rhythm, 
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mouse hearts from adrenergic-competent and deficient embryos were cultured 
ex vivo at E10.5, and heart rates were measured before and after challenge with 
the -adrenergic receptor agonist, isoproterenol (500 nM).  On average, all 
hearts showed increased heart rate responses following isoproterenol challenge, 
but a significant (p < 0.05) 225% increase in the arrhythmic index (AI) was 
observed only in adrenergic-deficient hearts.  These results show that adrenergic 
hormones may influence heart development by stimulating connexin 43 
expression, facilitating atrioventricular conduction, and helping to maintain 
cardiac rhythm during a critical phase of embryonic development. 
Introduction 
Mice that lack the ability to produce the adrenergic hormones, 
norepinephrine (NE) and epinephrine (EPI), due to targeted disruption of the 
dopamine -hydroxylase (Dbh) gene die at mid-gestation from apparent heart 
failure (Thomas et al., 1995).  Structural formation of the heart was not markedly 
perturbed in the adrenergic-deficient embryos, though subtle abnormalities such 
as dilated atria and disorganized ventricular myofibrils were observed in the 
deficient group.  In addition, blood pooling in major organs and slower in vivo 
heart rates led to the conclusion that heart failure was the likely cause of death in 
adrenergic-deficient embryos.  The mechanism of action appears to be primarily 
through -adrenergic receptor activation because isoproterenol (-agonist) but 
not L-phenylephrine (-agonist) could rescue the adrenergic-deficient (Dbh-/-) 
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mouse embryos when supplied via the maternal drinking water (Thomas and 
Palmiter, 1998).  Despite a relatively wide body of data on adrenergic 
mechanisms in the adult heart, only rudimentary information exists regarding 
adrenergic actions in the embryonic heart.  A major gap in our current knowledge 
is how embryonic activation of -adrenergic signaling specifically affects cardiac 
function and embryonic survival at these critical formative stages of development. 
Independent studies have shown that the heart itself is a source of 
adrenergic hormones during early development (Ebert et al., 1996; Ebert and 
Thompson, 2001; Huang et al., 1996).  “Intrinsic Cardiac Adrenergic” (ICA) cells 
appear in the heart at about the time that it first starts to beat (Ebert et al., 1996; 
Huang et al., 1996).  There is a transient clustering of ICA cells in regions of the 
heart progressively associated with development of the cardiac pacemaking and 
conduction system, including the pacemaker cells in the sinoatrial node, the 
atrioventricular node, bundle of His, and Purkinje fibers (Ebert and Thompson, 
2001).  Some of these transient ICA cells appear to differentiate into cardiac 
myocytes, including the specialized myocytes that serve as pacemaker cells in 
the sinoatrial and atrioventricular nodes as well as extensive labeling of myocytes 
throughout the ventricular conduction system (Ebert et al., 2004).  These 
observations have led us to hypothesize that NE and/or EPI play a critical role in 
the embryonic development of the cardiac pacemaking and conduction system 
(Ebert and Taylor, 2006). 
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In the present study, we utilized the Dbh knockout mouse model to test 
the hypothesis that NE and EPI play a critical role in the development of the 
cardiac pacemaking and conduction systems.  Our initial experiments evaluated 
the in situ expression of a key pacemaker channel protein, the hyperpolarization-
activated cyclic nucleotide-modulated channel isoform 4 (Hcn4) (Stieber et al., 
2003), and a major gap junction protein responsible for fast ventricular 
conduction, connexin 43 (Cx43) (van Veen et al., 2001), in adrenergic-competent 
and deficient embryos.  We then used microelectrode arrays (MEAs) to evaluate 
electrical conduction, and videomicroscopy to examine heart rate and rhythm.  
Our results indicate that while pacemaking activity appeared relatively unaffected 
by the absence or presence of adrenergic hormones, electrical conduction was 
impaired and susceptibility to arrhythmias was increased in adrenergic-deficient 
hearts relative to controls. 
Materials and Methods 
Animals 
The Dbh mouse strain and collection of embryos used in this study has been 
described previously [25].  All animal procedures were performed in accordance 
with NIH guidelines and were approved by the University of Central Florida 
Animal Care and Use Committee.  Most of our analyses were performed using 
embryonic day 10.5 (E10.5) mouse embryos because E10.5 is the latest stage of 
development when adrenergic-deficient embryos are still largely asymptomatic 
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(Thomas et al., 1995).  Since various secondary and other indirect effects of 
adrenergic deficiency may occur as a consequence of heart failure at later 
developmental stages, we confined our analyses to E10.5 and earlier stages in 
an attempt to identify more direct mechanisms of adrenergic action in the 
developing heart. 
Immunofluorescence histochemistry 
Dual immunofluorescent histochemical staining of hearts was performed 
essentially as described previously (Ebert et al., 2004; Ebert and Thompson, 
2001).  
Ex vivo embryonic mouse heart cultures 
E10.5 mouse hearts were isolated under aseptic conditions and cultured in 
Dubelcco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum 
(Hyclone Labs, Logan, UT) that had been charcoal-stripped to remove 
catecholamine and steroid hormones (Natarajan et al., 2004).  The media was 
additionally supplemented with the following (final concentrations given):  D-
glucose (25 mM), sodium pyruvate (1 mM), penicillin G (100,000 U/L), 
streptomycin (100 mg/L), β-mercaptoethanol (55 µM), l-glutamine (2 mM), and 
1% 100x α-minimum nonessential amino acids (Ebert et al., 2007).  Hearts were 
cultured for 20-24 hours prior to any measurements of beating activity or 
conduction properties. 
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Microelectrode arrays (MEAs) 
General MEA procedures were similar to those described previously (Pillekamp 
et al., 2006), with the exceptions described here.  Freshly isolated E10.5 hearts 
were placed in the center of gelatin-coated 8x8 MEAs (#200/10iR-Ti, 
Multichannel Systems, Reutlingen, Germany) with the flat ventral surface in 
contact with electrodes (i.e., outflow tract projecting upward).  A representative 
video of an E10.5 spontaneously beating mouse heart on a MEA is shown in 
Supplemental Video 3.  Electrodes were 10 µm in diameter and 200 µm apart.  
MEA analysis was performed using Clampfit v10.0.0.61 (Molecular Devices, 
Sunnyvale, CA). The first depolarizing atrial electrode was considered the 
sinoatrial region (SAR).  The electrode with the largest depolarization in the 
atrioventricular region was considered the atrioventricular junction (AVJ), and the 
ventricular apex (APX) was identified both by location and bifurcation of impulse 
propagation to the distal Purkinje fibers. Within the AVJ and APX regions, 
adjacent electrodes depolarized usually near-simultaneously (<0.5 ms of each 
other). Conduction time was measured between field potential minimums (FPmin) 
(Halbach et al., 2003; Reppel et al., 2004). 
Beating rate and rhythmicity measurements 
Beating rate and rhythmicity measurements were performed as described 
previously (Fink et al., 2009; Natarajan et al., 2004).  Arrhythmic index (AI) was 
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calculated as the median cycle length divided by the standard deviation (Fink et 
al., 2009). 
Statistics 
Data are expressed as mean ± S.E.M. Student t-tests were performed to 
compare means, with p < 0.05 required to reject the null hypothesis.  No 
significant differences were observed between wild-type (Dbh+/+) and 
heterozygous (Dbh+/-) hearts at E10.5 in any examined parameter. Since there 
was no significant difference between Dbh+/+ and Dbh+/- embryos (Thomas et al., 
1995), these two genotypes were combined into a single group referred to as 
“adrenergic-competent."  In contrast, homozygous knockout (Dbh-/-) mice were 
designated as “adrenergic-deficient” due to their inability to produce NE or EPI 
(Thomas et al., 1995). 
Results 
Since ICA cells have previously been identified in regions of the 
developing heart associated with conduction and pacemaking function (Ebert et 
al., 2004; Ebert and Thompson, 2001), we employed immunofluorescent 
histochemical staining to evaluate a key pacemaking protein (Hcn4) and a major 
gap junction protein (Cx43) important for the generation and propagation, 
respectively, of electrical signaling in adrenergic-competent and deficient 
embryonic hearts.  As shown in Fig. 4, our results indicate that Cx43 
immunofluorescent staining intensity in adrenergic-deficient hearts was 
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substantially less than that observed in adrenergic-competent hearts (compare 
red fluorescence in panels a and b).  In this example, co-immunofluorescent 
staining with Hcn4 showed similar distribution and intensity in both groups. 
Higher magnification of the dual immunofluorescent staining in the SAN region is 
shown in panels c and d.  The arrowhead points to red Cx43-expressing cells 
while the arrow indicates the Hcn4-expressing cells shown in green.  Cx43-
expressing cells showed only marginal overlap with Hcn4-positive cells in the 
SAN region, but were found in the adjacent atrial myocardial cells and extending 
into the myocardium of the ventricle and outflow tract regions as well.  This was 
true for both adrenergic-competent and deficient E10.5 hearts, though the 
intensity of the Cx43 staining in the deficient hearts was much less than that 
seen in the competent hearts (compare panels c and d).  This effect appeared to 
be specific for Cx43 since anti-sarcomeric α-actinin staining in adjacent sections 
showed similar intensity and distribution for both adrenergic-competent and 
deficient hearts (compare red staining in panels e and f).  Further, since the 
same secondary antibody source and concentration were used for both 
sarcomeric -actinin and Cx43, the relative decrease in Cx43 staining intensity 
was probably not due to differential effects of the secondary antibody, but instead 
likely reflects changes in Cx43 expression resulting from lack of adrenergic 
stimulation.  
We similarly analyzed other regions of the heart, and found that Cx43 
immunofluorescent histochemical staining was also decreased in the 
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atrioventricular (A-V) area of adrenergic-deficient compared to adrenergic-
competent E10.5 embryos (Fig. 5).  Low-magnification views of sarcomeric 
αactinin immunofluorescent staining in adrenergic-competent and deficient 
hearts (panels a and b) are provided to aid in orientation of the higher-
magnification views of Cx43 staining in these same sections, as shown in panels 
c-f.  When camera exposure times and image processing were optimized for 
viewing of Cx43 in adrenergic-competent E10.5 mouse hearts, virtually no Cx43 
staining was observed in the A-V junctional region of adrenergic-deficient hearts 
using equivalent image acquisition and processing settings (compare panels c 
and d, “dim”).  Cx43 was not entirely absent from the A-V region of the 
adrenergic-deficient hearts, however, as it can be seen when image processing 
was adjusted to increase sensitivity.  Equivalent processing of the images from 
adrenergic-competent hearts led to overexposure of Cx43 immunofluorescent 
staining, though the comparison with the deficient example under the same 
conditions (“bright”) still clearly demonstrate the disparity of staining intensities 
between adrenergic-competent and deficient E10.5 in the A-V regions (compare 
panels e and f).  These results further demonstrate that Cx43 expression is 
selectively diminished in E10.5 adrenergic-deficient myocardium relative to that 
found in adrenergic-competent hearts at this stage of development. 
When examined one day earlier in development (E9.5), however, Cx43 
staining intensity and distribution appeared similar in adrenergic-competent and 
deficient mouse hearts (Fig. 6).  Hcn4 immunostaining was also similar between 
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these groups at E9.5 (compare panels a and b).  Comparative views of Cx43 are 
shown at low (panels c and d) and high (panels e and f) magnification.  These 
results demonstrate that the Cx43 immunofluorescent staining is not inherently 
diminished in adrenergic-deficient hearts throughout development, suggesting 
that decreased Cx43 expression occurs after E9.5.   
To determine if the electrical properties of the developing embryonic heart 
were altered as a result of adrenergic-deficiency, we cultured isolated E10.5 
adrenergic-competent and deficient hearts on MEAs and measured extracellular 
field potentials from different regions of the heart.  These included the sinoatrial 
region (SAR) near the SAN (sinoatrial node), the interchamber atrioventricular 
junction region (AVJ), and ventricular apex (APX), as illustrated in Fig. 7.  
Representative field potential traces from adrenergic-competent and deficient 
hearts are shown from simultaneous MEA recordings at the SAR and APX 
electrodes, indicating a general lengthening of the conduction time from SAR to 
APX in deficient hearts.  MEA measurements were thus obtained for a series of 
these ex vivo embryonic heart preparations, and the combined results are 
summarized in Table 1, where it can be seen that the atrioventricular conduction 
time (AVJ-APX), which includes transmission time through the AVJ, was roughly 
twice the duration in adrenergic-deficient hearts compared with competent 
control hearts (31±6 vs. 15±2 ms, respectively, n=5/6, p < 0.05).  In contrast, 
atrial conduction times (SAR-AVJ) were not significantly altered between the 
groups.  The adrenergic-deficient hearts displayed slightly slower intrinsic heart 
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rates and longer SAR-APX conduction times than adrenergic-competent controls 
on average, but these differences were not significant.  These data suggest that 
there was a selective slowing of atrioventricular conduction velocity in 
adrenergic-deficient E10.5 hearts whereas atrial conduction and average beating 
rates were not significantly altered under these conditions. 
To determine if adrenergic-deficient embryonic mouse hearts show 
increased susceptibility to arrhythmia, we cultured adrenergic-deficient and 
adrenergic-competent hearts ex vivo following isolation at E9.5 and E10.5.  Heart 
rate and rhythmicity were measured at baseline and after challenge with the -
adrenergic receptor agonist, isoproterenol (500 nM).  This challenge resulted in 
consistent 30-40% increase in heart rates for all groups within 2 minutes after 
drug application (Fig. 8a).  Baseline and isoproterenol-induced heart rates were 
not significantly different between adrenergic-deficient and competent hearts at 
either E9.5 or E10.5 (Supplemental Table).  Arrhythmic index (AI) was used to 
measure the rhythmicity of these isolated hearts before and after isoproterenol 
treatment as previously reported and described in the Materials and Methods 
section [9].  A significant (p < 0.05) 225% increase in AI from the adrenergic-
deficient E10.5 mouse hearts was observed following the isoproterenol challenge 
(Fig. 8b).  Representative examples of adrenergic-competent (rhythmic beating) 
and adrenergic-deficient (arrhythmic beating) hearts are provided in 
Supplemental Videos 1 and 2, respectively.  Relatively small non-significant (p > 
0.05) increases in AI (< 50%) were observed for adrenergic-competent hearts at 
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E10.5, and no significant differences were observed in AI for either group at E9.5 
(Fig. 8b).  These results demonstrate that by E10.5, adrenergic-deficient mouse 
hearts were significantly more arrhythmic compared with adrenergic-competent 
controls following acute challenge with isoproterenol. 
Discussion 
In the present study, we showed that adrenergic deficiency during 
embryonic development leads to increased susceptibility for cardiac arrhythmias, 
slowed atrioventricular conduction, and decreased expression of the major 
cardiac gap junction protein, Cx43.  We also showed that sarcomeric -actinin 
and Hcn4 expression patterns and intensities were similar in adrenergic-
competent and deficient hearts, thereby suggesting that myocardial and 
pacemaker cell development are grossly normal in the absence of NE and EPI.  
These results are supported by the finding that heart rates were not significantly 
different in adrenergic-competent and deficient hearts.  Taken together, these 
results suggest that adrenergic hormones are not required for the development of 
cardiac pacemaking activity through E10.5 in the mouse, but instead function to 
stimulate Cx43 expression, facilitate atrioventricular conduction, and maintain 
cardiac rhythmicity. 
Initially, we aimed to examine protein staining intensity and distribution 
patterns for Cx43 and Hcn4 to determine if these are altered in adrenergic-
deficient embryonic hearts around the time of their demise.  Cx43 staining was 
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less intense relative to that for sarcomeric -actinin and Hcn4 in adrenergic-
deficient hearts compared with competent controls at E10.5.  Our co-
immunofluorescent histochemical staining data show that was not true one day 
earlier at E9.5, where Cx43 expression was not diminished in adrenergic-
deficient hearts relative to controls or to sarcomeric -actinin and Hcn4 staining.  
These results indicate that Cx43 appears to develop normally through E9.5 in 
adrenergic-deficient hearts, but that it either becomes down-regulated or fails to 
be up-regulated due to the lack of NE and EPI, such that by E10.5, Cx43 
expression was substantially lower in adrenergic-deficient hearts than in controls.  
The pattern of Cx43 distribution, which remained diffuse and spotty, as has been 
seen in other studies at these early developmental stages (Coppen et al., 2003; 
Delorme et al., 1997; Fromaget et al., 1992; Peters et al., 1994), did not appear 
to be altered in adrenergic-deficient mouse hearts, but the intensity of the 
staining for Cx43 was substantially reduced compared with equivalent staining in 
the control group. 
Disruption of both Cx43 alleles (Cx43-/-) results in lethality at birth due to 
cardiac malformation resulting from swelling and blockage of the right outflow 
tract (Reaume et al., 1995).  Surprisingly, cardiac conduction speeds were not 
altered much at E12.5, the earliest developmental timepoint measured in Cx43-/- 
hearts, though significant slowing became apparent by E15.5 and continued to 
lengthen thereafter (Vaidya et al., 2001).  Cardiac-restricted Cx43 knockouts 
survive through birth, but die within the first two months of life from sudden 
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cardiac death due to severe arrhythmias (Gutstein et al., 2001).  Ventricular 
conduction velocity was also markedly slowed in these animals.  Additionally, 
cultured embryonic myocytes derived from Cx43-/- hearts show dramatic 
reductions in conduction speeds relative to Cx43+/- or Cx43+/+ controls 
(Beauchamp et al., 2004).  Thus, it is well-established that Cx43 plays a critical 
role in mediating ventricular conduction through the fetal and early postnatal 
periods.  At earlier stages of embryonic development, it may be less critical as 
compensation by Cx40 and Cx45 appear to help ameliorate conduction slowing 
due to the absence of Cx43 (Vaidya et al., 2001), though there is evidence 
suggesting that expression and activity may also be compromised in Cx43-/- 
myocytes (Beauchamp et al., 2004; Johnson et al., 2002; Kirchhoff et al., 2000; 
Xie et al., 2009).  These caveats notwithstanding, lowered Cx43 expression in 
adrenergic-deficient hearts could contribute to the observed slowing of 
atrioventricular conduction.  We expect to find additional targets of embryonic 
adrenergic hormone action in the developing heart that will also likely contribute 
to the slowed atrioventricular conduction and arrhythmogenic phenotype of 
adrenergic-deficient mice. 
Microelectrode arrays provided ex vivo heart rate and conduction analysis 
of cultured adrenergic-competent and deficient embryonic hearts.  One of the 
limitations of the MEA analysis, however, was the relatively large electrode-
electrode distance (200 µm) compared to the small heart (~600 x ~800 µm).  In 
addition, the 2-dimensional MEA surface could only examine the ventral plane of 
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the 3-dimensional heart.  Despite these limitations, the data from the MEA 
experiments demonstrated that atrioventricular conduction was slower in 
adrenergic-deficient hearts.  Of note, it has been reported that E10.5 is 
approximately the stage of development in the mouse when ventricular 
conduction transitions from a base-to-apex to an apex-to-base pattern of 
excitation (Rentschler et al., 2002).  It is therefore conceivable that adrenergic 
hormones could play a role in mediating this transition in the developing heart.  
Future experiments are needed to further explore the underlying molecular 
mechanisms that mediate adrenergic influence on the development of 
atrioventricular conduction. 
Failure to complete this transition in a coordinated and timely manner 
could have critical consequences for heart development and embryonic survival if 
the myocardium becomes more susceptible to arrhythmogenesis.  Adrenergic-
competent and deficient embryonic hearts did not show a difference in basal AI; 
however, isoproterenol challenge did induce significantly increased AI in 
adrenergic-deficient E10.5 hearts compared to controls.  This indicates that in ex 
vivo cultured conditions adrenergic hormones help maintain a balance of 
rhythmic beating even after increased stimulation.  Other mechanisms of -
adrenergic regulation, such as synchronization of intracellular Ca2+ oscillations 
(Song et al., 2001), may also impact arrhythmia susceptibility in adrenergic-
deficient hearts.  Consequently, we cannot say for certain if the altered Cx43 
expression and slowed atrioventricular conduction observed in adrenergic-
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deficient hearts were contributory to the increased propensity for arrhythmias.  If 
such arrhythmias are triggered in vivo, they could certainly contribute to the 
observed heart failure and fetal lethality in adrenergic-deficient mice, but further 
study is required to make that determination. 
In summary, we have shown that adrenergic deficiency led to decreased 
Cx43 in E10.5 but not E9.5 mouse hearts.  We have also for the first time shown 
that atrioventricular conduction is significantly slower in adrenergic-deficient 
hearts, and that arrhythmic activity was significantly induced in adrenergic-
deficient hearts compared with adrenergic-competent controls.  In contrast, 
pacemaking cell development and gross cardiac structural development of the 
early muscle chambers appear relatively normal in adrenergic-deficient embryos 
through E10.5.  Thus, our data do not support the hypothesis that adrenergic 
hormones are critical for development of cardiac pacemaking, but they are 
supportive of a role for adrenergic hormones in stimulating Cx43 expression, 
facilitating atrioventricular conduction, and helping to maintain cardiac rhythm 
during a critical early period of embryonic heart development. 
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Tables 
Table 1 Summary of MEA data from E10.5 mouse hearts. 
 Adrenergic- 
Competent 
Adrenergic- 
Deficient 
Heart Rate (bmp) 
 
148.6 ± 10.7 
(11) 
120.7 ± 6.7 
(6) 
Conduction Time: SAR-APX (ms) 
 
52.1 ± 4.0 
(11) 
64.8 ± 9.1 
(6) 
Conduction Time: SAR-AVJ (ms) 
 
33.8 ± 3.0 
(6) 
29.8 ± 4.8 
(5) 
Conduction Time: AVJ-APX (ms) 
 
15.4 ± 1.7 
(6) 
31.4 ± 6.4 * 
(5) 
*, p < 0.05 
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Table 2 Values for heart rate and arrhythmic index responses to 
isoproterenol challenge in adrenergic-competent and deficient embryonic 
mouse hearts isolated at E9.5 (a) and E10.5 (b). 
 
a. Heart rate and arrhythmic index at baseline and in response to isoproterenol in 
E9.5 adrenergic-competent and deficient embryos. 
 
 Adrenergic-competent (5) Adrenergic-deficient (4) 
  
Baseline 
 
 
Isoproterenol 
 
 
Baseline 
 
 
Isoproterenol 
 
 
Heart Rate (bpm) 
 
119.6 ± 9.8 
 
160.0 ± 14.6 
 
 
137.3 ± 7.8 
 
177.5 ± 6.6 
     
 
Arrhythmic Index  
 
 
0.03 ± 0.01 
 
0.02 ± 0.001 
 
0.04 ± 0.03 
 
0.02 ± 0.003 
 
b. Heart rate and arrhythmic index at baseline and in response to isoproterenol in 
E10.5 adrenergic-competent and deficient embryos. 
 
 Adrenergic-competent (17) Adrenergic-deficient (5) 
  
Baseline 
 
 
Isoproterenol 
 
 
Baseline 
 
 
Isoproterenol 
 
 
Heart Rate (bpm) 
 
112.7 ± 
10.1 
 
159.6 ± 12.6 
 
 
148.8 ± 
15.2 
 
206.4 ± 16.1 
     
 
Arrhythmic Index  
 
 
0.06 ± 0.01 
 
0.05 ± 0.01 
 
0.04 ± 0.02 
 
0.08 ± 0.02 
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Figures 
 
Figure 4 Immunofluorescent histochemical evaluation of Cx43 relative to 
Hcn4 and sarcomeric α-actinin expression in adrenergic-competent and 
deficient E10.5 mouse hearts. 
(a,b) Low-magnification (Lo-Mag, 20X objective) views of adrenergic-competent 
and deficient mouse hearts, respectively, for Cx43 (red) and Hcn4 (green).  Co-
localized areas appear yellow.  Scale bar for panels a-b, 0.1 mm.  (c,d)  High-
magnification (Hi-Mag, 60X objective) views of the corresponding SAN regions 
(arrows) depicted in panels a and b, respectively, for adrenergic-competent and 
deficient hearts stained for Cx43 and Hcn4.  (e,f)  Hi-Mag view of an adjacent 
section co-stained for sarcomeric α-actinin (red) and Hcn4 (green) in adrenergic-
competent and deficient hearts.  Arrow indicates Hcn4 staining (a-f), and 
arrowhead indicates either Cx43 (a-d) or α-actinin (e,f) in approximately 
equivalent regions of each heart.  Scale bar for panels c-f, 25 µm. 
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Figure 5 Immunofluorescent histochemical evaluation of Cx43 expression 
in the A-V junction region of adrenergic-competent and deficient E10.5 
mouse hearts.  
(a, b) Low magnification (10X) objective of adrenergic-competent and deficient 
heart sections stained for sarcomeric α-actinin.  Scale bar for a-b 200 µm. (c,d) 
Cx43 staining in the A-V junction region when pixel levels are optimized for 
staining in the adrenergic-competent specimens (“dim”).  (e, f) Same image as in 
panels c and d, respectively but shown under “bright” conditions to optimize for 
Cx43 appearance in the adrenergic-deficient specimens.  Scale bar for c-f, 50 
µm. 
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Figure 6 Immunofluorescent histochemical evaluation of Cx43 and Hcn4 
expression in adrenergic-competent and deficient E9.5 mouse hearts. 
(a,b) Hcn4 (green) staining (arrows) in adrenergic-competent and deficient 
hearts, respectively.  (c,d)  Cx43 (red) staining (arrow) in adrenergic-competent 
and deficient hearts, respectively.  Scale bar for a-d, 50 µm.  (e,f)  Expanded 
view of the Cx43 (boxed insets from panels c and d) in adrenergic-competent 
and deficient hearts, respectively.  Scale bar for e-f, 25 m. 
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Figure 7 Illustrative conduction paths and representative field potential 
traces from adrenergic-competent and deficient E10.5 mouse hearts 
cultured ex vivo on MEAs. 
(a) Representative heart shown without anchoring grid for visual clarity. Circle 
indicates first electrode to depolarize in the sinoatrial region (SAR).  Boxes 
indicate electrodes depolarizing near-simultaneously (within 0.5 ms of each 
other) in the atrioventricular junction region (AVJ) and ventricular apex (APX).  
Arrows display overall evaluated conduction paths. (b,c)  Representative field 
potential recordings were aligned and compared from the SAR and APX regions 
of adrenergic-competent and deficient hearts, respectively.  Vertical dashed lines 
were drawn to show how conduction times were measured from the FPmin (see 
Materials and Methods for more details on how these measurements were 
performed) [9].  Cumulative data from several experiments is shown in Table 1. 
Figure contributed courtesy of Dr. David Taylor. 
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Figure 8 Heart rate and arrhythmic index responses to isoproterenol 
challenge in adrenergic-competent (black columns) and adrenergic-
deficient (white columns) embryonic mouse hearts isolated at E9.5 and 
E10.5. 
(a)  Percent change in heart rates following acute (2-min) challenge with 0.5 M 
isoproterenol.  (b)  Percent change in arrhythmic index (AI) in response to acute 
isoproterenol (0.5 M) challenge in adrenergic-competent and deficient 
embryonic mouse hearts.  *, p < 0.05 relative to control adrenergic-competent 
E10.5 hearts. 
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CHAPTER THREE:  
IMPAIRED CARDIAC ENERGY METABOLISM IN EMBRYOS 
LACKING ADRENERGIC STIMULATION 
Abstract 
We hypothesize that adrenergic hormones play a vital role in development 
by providing critical stimulation of energy metabolism during the embryonic/fetal 
transition period.  To test this hypothesis, we examined ATP and ADP 
concentrations in mouse embryos lacking the ability to produce the adrenergic 
hormones, norepinephrine and epinephrine, due to targeted disruption of the 
essential dopamine -hydroxylase (Dbh) gene.  Our results show that embryonic 
ATP concentrations decreased dramatically while ADP concentrations rose such 
that the ATP/ADP ratio in the adrenergic-deficient group was nearly 50-fold less 
than that found in littermate controls by embryonic day 11.5.  We also found that 
extracellular acidification and oxygen consumption rates were significantly 
decreased, and mitochondria were drastically larger and more branched in 
adrenergic-deficient hearts.  Metabolic deficiencies in Dbh-/- embryos were 
prevented by administration of the β-adrenergic agonist, isoproterenol.   These 
data demonstrate that adrenergic hormones stimulate cardiac energy metabolism 
during a critical period of embryonic development. 
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Introduction 
The adrenergic hormones, epinephrine (EPI) and norepinephrine (NE), 
are key mediators of stress responses and sympathetic nervous system activities 
in adult mammals.  NE, in particular, is also essential for embryonic 
development.  Targeted disruption of the gene dopamine β-hydroxylase (Dbh), 
which codes for the enzyme that converts dopamine into NE, led to a loss of NE 
and EPI, and embryonic lethality due to heart failure in mice (Thomas et al., 
1995).  In contrast, disruption of the subsequent enzymatic step catalyzed by 
phenylethanolamine n-methyltransferase (Pnmt) led to the loss of EPI without 
concomitant developmental phenotypes (Ebert et al., 2004).  Thus, while EPI 
may contribute to adrenergic activity in the embryo, NE is clearly of critical 
importance for heart development. 
How NE influences heart development in utero is not fully understood.  In 
Dbh-/- embryos signs of cardiac distress begin to appear on embryonic day 10.5 
(E10.5), and approximately 50% of the Dbh-/- embryos die by E11.5 (Thomas et 
al., 1995).  Remarkably, the heart appears to develop and function normally up to 
this point, but then deteriorates rapidly into heart failure within 24h of the first 
symptoms, which include sluggish cardiac contractions, arrhythmia, and 
asynchrony as observed via echocardiography in utero (Osuala et al., 2012).  
Recent work has shown that Dbh-/- hearts display significantly delayed 
conduction speed across the atrioventricular junction relative to age-matched 
littermate controls (Baker et al., 2012).  These results suggest important 
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adrenergic influences on the development of cardiac structure and function, but 
do not fully explain how NE affects them. 
At these early embryonic stages of development, there is no sympathetic 
innervation of the heart, and the adrenal glands have not yet formed.  Instead, 
NE is produced in the embryonic heart itself, as well as outside of the heart in 
primordial sympathetic ganglia and brainstem neurons (Ebert et al., 1996; Ebert 
et al., 2004; Ebert and Thompson, 2001).  With respect to heart function, NE 
appears to be acting primarily through β-adrenergic receptors since Dbh-/- 
embryos could be rescued by providing the β-agonist, isoproterenol, in the 
maternal drinking water, whereas the α-agonist, l-phenylephrine, was ineffective 
at rescuing the heart failure and lethality (Thomas and Palmiter, 1998).  These 
results established that NE stimulates cardiovascular functions during the early 
embryonic period primarily through β-adrenergic receptors.  But what are the 
important downstream pathways and targets affected by β-adrenergic receptor 
stimulation in the embryonic heart? 
To gain insight about adrenergic actions in cardiac development, we 
recently performed a genome-wide expression screen of Dbh-/- and Dbh+/+ 
embryonic hearts.  A key finding from this screen demonstrated the largest 
category of differentially expressed genes (~31% of total) were those involved in 
metabolism (Osuala et al., 2012).  In adult mammals, adrenergic hormones are 
known to have profound and widespread influences on metabolism.  In the liver, 
for example, β-adrenergic stimulation inhibits glycolysis, promotes 
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gluconeogenesis, and stimulates breakdown of glycogen (Berthet et al., 1957; 
Sutherland and Wosilait, 1955).  In cardiac and skeletal muscle, glycolysis and 
oxidative phosphorylation (OXPHOS) are increased in response to β-adrenergic 
stimulation to produce more available energy during stress.  Free fatty acids are 
released from adipose tissue, and these serve as the primary fuel source for 
cardiac metabolism in adult mammals, but prior to birth the heart principally uses 
carbohydrates (Bing et al., 1954; Carlsten et al., 1961; Cox and Gunberg, 1972; 
Ellington, 1987; Gordon and Cherkes, 1956; Neely and Morgan, 1974; Shepard 
et al., 1970).  The shift from carbohydrate to lipid metabolism in the heart occurs 
shortly after birth and is often referred to as the “fetal-shift” in cardiac metabolism 
(Duncan, 2011; Madrazo and Kelly, 2008; Makinde et al., 1998).  Surprisingly 
little, however, is known regarding adrenergic influences on cardiac metabolism 
during the embryonic period. 
There is compelling evidence indicating that aerobic metabolism in the 
mitochondria becomes increasingly important as the heart transitions from 
embryonic to fetal stages of development.  For example, genetic mutations that 
decrease or disrupt OXPHOS often result in heart failure and embryonic lethality 
(Humble et al., 2013; Larsson et al., 1998; Li et al., 2000).  Furthermore, 
mutations that disrupt mitochondrial structure and function also interfered with 
cardiomyocyte differentiation and development(Chen et al., 2003; Chen et al., 
2011; Davies et al., 2007; Wakabayashi et al., 2009), and many of these 
ultimately succumbed to heart failure and embryonic lethality.  Thus, there 
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appears to be an “embryonic-shift” from primarily anaerobic to aerobic metabolic 
mechanisms in the heart during the embryonic-fetal transition period of 
development (Baker and Ebert, 2013).   
We hypothesize that adrenergic hormones play a critical role in facilitating 
the metabolic shift towards aerobic oxidative phosphorylation in cardiac 
mitochondria during embryonic development.  Here, we test this hypothesis by 
examining metabolic profiles of ATP, ADP, and ATP/ADP ratios in Dbh-/- and 
control embryos.  In parallel, we also examine other metabolic indices, including 
cardiac oxygen consumption rate (OCR) and extracellular acidification rate 
(ECAR) as estimators of aerobic and anaerobic metabolism, respectively.  In 
addition, we performed detailed ultrastructural analysis of mitochondria in 
adrenergic-deficient and control hearts.  As described in the next section, our 
results show that both anaerobic and aerobic metabolism are compromised in 
Dbh-/- hearts. 
Materials and Methods 
Mice  
All procedures and handling of mice were conducted in accordance with The 
University of Central Florida Institutional Animal Care and Use Committees.  The 
Dbh mouse strain was kindly provided by Dr. Richard Palmiter (University of 
Washington, Seattle, WA) (Thomas et al., 1995) and maintained as previously 
described (Baker et al., 2012; Osuala et al., 2012).  Timed pregnancies were 
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determined by the presence of a vaginal plug (denoted as E0.5) and further 
confirmed by high-resolution ultrasound (Vevo 2100 instrument with 40 MHz 
transducer; Visualsonics, Inc.) at E8.5.  For isoproterenol rescue, maternal 
drinking water was supplemented with 0.02 mg/ml isoproterenol and 2.0 mg/ml 
vitamin C beginning at E8.5, as previously described (Thomas and Palmiter, 
1998). 
Reagents 
Chemical reagents were purchased from Sigma-Aldrich, St. Louis, MO, unless 
otherwise noted.  Electron microscopy grade reagents for TEM were purchased 
from Electron Microscopy Sciences, Hatfield, PA.  Cell culture reagents were 
purchased from Invitrogen, Grand Island, NY.  
Embryonic tissue collections  
All embryos used in this study appeared to be healthy and viable at the time of 
isolation as judged by their size (crown-rump lengths), color, texture, 
morphology, and overall appearance.  Microscopic examination confirmed a 
beating heart and bright red blood coursing through the embryonic circulation.  
Unhealthy and dead embryos were discarded.  From the living specimens 
collected, no apparent differences were observed between adrenergic-deficient 
and control embryos based on these gross examinations at the time of isolation.  
Upon isolation, the heads were removed and used for genotyping.  For enzyme 
assays, trunks were flash-frozen in liquid nitrogen and stored at -80ºC.  For some 
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experiments, E10.5 and E11.5 mouse hearts were isolated under aseptic 
conditions and cultured in DMEM containing 10% fetal bovine serum (Hyclone 
Labs) that had been charcoal-stripped to remove catecholamine and steroid 
hormones (Natarajan et al., 2004).  The media was additionally supplemented 
with penicillin G (100,000 U/L) and streptomycin (100 mg/L).  Hearts were 
cultured for 24 hours prior to any measurements of oxygen consumption or 
extracellular acidification rates. 
ATP and ADP measurements  
ATP and ADP measurements were performed with an Aposensor™ ATP/ADP 
Ratio Bioluminescence Assay Kit (Biovision) as per manufacturer’s instructions.  
Briefly, embryonic tissue was homogenized in 6% trichloroacetic acid (TCA) for 1 
min then centrifuged at 6,000 g for 5 min at 4ºC.  The supernatant was then 
removed, and TCA was neutralized with tris-acetate as previously described 
(Cosen-Binker et al., 2006).  ATP measurements were performed with ATPlite™ 
Bioluminescence Assay (Perkin Elmer) as instructed by the manufacturers’ 
protocol.  Standard curves were generated with known concentrations of ATP.  
Luminescence was detected in an Envision Multilabel plate reader (Perkin 
Elmer), and ATP measurements were normalized to total protein concentrations. 
Lactate measurements  
Embryos were homogenized in 8% perchloric acid for 1 min then centrifuged at 
6,000 g for 4 min.  Absorbance readings at 340 nm before and after addition of L-
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lactate dehydrogenase was performed as described (Bergmeyer, 1974).  The 
supernatants for lactate measurements were combined with NAD solution (2.5 M 
NAD, 0.2 M Glycine buffer, and 100 µL ≥500 units/mg protein L-lactate 
dehydrogenase from bovine heart).  Increase in absorbance at 340 nm was 
compared to a standard curve of known lactate concentrations.  Lactate 
measurements were normalized to total protein concentrations. 
Glucose measurements  
Glucose was measured in triplicate using a WaveSense Presto blood glucose 
monitoring system and compared to a standard curve of known D-glucose 
concentrations. 
Oxygen consumption rate and Extracellular acidification rate measurements  
Hearts were isolated and cultured, as described above, in Seahorse Biosciences 
XF24 Islet Capture Microplate with mesh grids placed on top of the specimen to 
prevent it from floating and from probe interference.  After 24 hrs culture media 
was removed and replaced with serum free Seahorse XF Assay media and basal 
oxygen consumption and extracellular acidification rates were simultaneously 
measured with a Seahorse XFe system (Seahorse Biosciences) at 10-min 
intervals over a period of 2 hrs.  Rotenone (0.5 µM) and antimycin A (2 µM) were 
added through separate injection ports (Zhang et al., 2012). 
55 
 
Transmission Electron Microscopy 
Experiments were performed as previously described (Song et al., 2011).  Briefly, 
isolated embryonic hearts were placed in Karnovsky’s fixative (2% 
paraformaldehyde, 2.5% glutaraldehyde and 0.1 M sodium cacodylate) for 1 
hour.  Samples were then rinsed in 0.1 M sodium cacodylate with 3 µM CaCl2 
and post-fixed in a 1% osmium tetroxide, 0.8% potassium ferrocyanide and 3 µM 
CaCl2 solution.  Samples were en bloc stained with 2% uranyl acetate and 
dehydrated in graded ethanol solutions.  Samples were embedded in Durcupan, 
and thin sections were cut at 80nm using a Leica UTC Ultramicrotome and 
diamond knife, and then mounted on copper grids.  Thin sections were stained 
with routine TEM double stain:  Four minutes in 4% Uranyl Acetate.  Four 
minutes in Reynolds Lead Citrate.  Thin Sections were examined using an FEI 
268D TEM at 50Kv, and digital images recorded using an AMT XR-60 digital 
camera.  Mitochondrial morphometric analyses were performed with ImageJ 
software (NIH). 
JC-1 dye 
Myocytes were isolated and cultured on coverglass (for microscopy) or 48-well 
plates (for flow cytometry) as described previously (Maltsev et al., 1994).  
Cardiomyocytes were cultured for 48 hours before staining with 5 µg/mL JC-1 
dye (Invitrogen) for 20 min.  Dye was washed with PBS and samples were either 
viewed using a Perkin Elmer Spinning Disk confocal microscope or quantified 
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using a BDFacs Canto flow cytometer (BD Biosciences, Inc.).  Gates were set 
with unstained cells and carbonyl cyanide-p-trifluoromethoxyphenylhydrazone 
(FCCP, 50 µM) treated controls and quantified emission filters appropriate for 
Alexa Fluor® 488 nm and R-phycoerythrin.  Data were analyzed using 
FCSExpress software (DeNovo). 
Gene Expression  
RNA was isolated using TRIzol reagent, and converted to cDNA using High 
Capacity cDNA reverse Transcription Kit (Invitrogen).  Real-time PCR was 
performed using SYBR Green Fast reagent in an AB7500 machine (Applied 
Biosystems).  Genes of interest were normalized to the housekeeping gene 
GAPDH.  Forward and reverse primers were as follows: Pgc-1α, 5’-
TATGGAGTGACATAGAGTGTGCT-3’ and 5’-CCACTTCAATCCACCCAGAAAG-
3’ Primer Bank ID 6679433a1, Tfam, 5’-GAGCGTGCTAAAAGCACTGG-3’ and 
5’-CCACAGGGCTGCAATTTTCC-3’ (Lagouge et al., 2006), Sirt1, 5’-
TGTGAAGTTACTGCAGGAGTGTAAA-3’ and 5’-
GCATAGATACCGTCTCTTGATCTGA-3’(Lagouge et al., 2006), Gapdh, 5’-
CCATCACCATCTTCCAGGAGCG-3’ and 5’-AGAGATGACCCTTTTGGC-3’ 
(Osuala et al., 2012).  mtDNA content was measured as described previously 
(Park et al., 2012). 
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Oil Red O Staining 
Oil Red O (5 mg/mL in isopropanol) stock stain was diluted to the working 
solution (30 ml of the stock stain diluted with 20 ml of distilled water), and used to 
stain for fat droplets, as previously described (Sengupta et al., 2013).  Briefly, the 
slides were air-dried, fixed in formalin, and briefly washed with running tap water 
for 1 min. They were then rinsed with 60% isopropanol, stained with freshly 
prepared Oil Red O working solution for 15-min.  The staining solution was then 
removed and the samples were rinsed with 60% isopropanol, rinsed further with 
distilled water, and mounted using Vectashield mounting medium (Vector Labs).  
Digital micrographs were obtained using a Leica DM2000 microscope, and 
images were analyzed for lipid droplets using NIH ImageJ software. 
Free Fatty Acid Quantification 
Fatty Acids were measured using the Free Fatty Acid Quantification 
Colorimetric/Fluorometric Kit (Biovision) according to the manufacturer’s 
instructions.  Briefly, flash-frozen embryos were homogenized for 30-sec then 
centrifuged at 12,000 g for 1 min.  100 µL 1% Triton-X 100 in chloroform was 
added to the supernatant.  Samples were centrifuged at 12,000 g for 10 min and 
lower phase was transferred and allowed to air dry, pellets were then 
resuspended in fatty acid buffer.  After following manufacturer’s protocol 
fluorescence readings were conducted in an Envision Multilabel plate reader 
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(Perkin Elmer) (Excitation: 535nm and Emission: 590 nm) and compared to 
palmitic acid standard curve.  Samples were measured in duplicate.Statistics  
Data are expressed as mean ± SEM. Student t-tests were performed to compare 
means, with p < 0.05 required to reject the null hypothesis.   
Results 
ATP is depleted in adrenergic-deficient embryos 
To determine if adrenergic deficiency affects embryonic metabolism, we 
measured ATP and ADP concentrations in adrenergic-competent (Dbh+/- and 
Dbh+/+) and deficient (Dbh-/-) embryos.  Throughout this and previous studies, we 
observed no significant difference in Dbh+/+ and Dbh+/- embryos for any assays 
employed, and these genotypes are phenotypically indistinguishable.  Thus we 
have combined Dbh+/+ and Dbh+/- mice into a single group that we will hereafter 
refer to as “adrenergic-competent”.  Dbh-/- mice fail to produce NE or EPI, and 
most will succumb to heart failure and embryonic lethality between E10.5-
E15.5(Thomas et al., 1995) unless rescued by maternal supplementation of 
alternative catecholamine substrates(Thomas et al., 1995) or β-adrenergic 
agonists, such as isoproterenol (ISO) (Thomas and Palmiter, 1998). 
In the absence of any rescue, ATP concentrations begin to show 
significant decreases in adrenergic-deficient embryos as early as E10.5, and 
decline precipitously by E11.5 (Figure 9A).  Conversely, ADP concentrations 
increased over the same time period in the Dbh-/- group relative to controls 
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(Figure 9B).  Notably, both ATP and ADP concentrations were unchanged at 
E9.5 relative to adrenergic-competent controls (Figure 9A, and 9B).  Absolute 
ATP, ADP, and ATP/ADP values, generated from known ATP and ADP standard 
curve concentrations, are shown in Table 3 for adrenergic-competent and 
deficient embryos.   
This is seen most clearly by examining the ATP/ADP ratio.  At E9.5, for 
example, ATP/ADP ratios were virtually identical in adrenergic-competent and 
deficient embryos, but then diverge dramatically over the next two days.  In 
control embryos, the ATP/ADP ratio steadily increases over this time period, but 
in Dbh-/- embryos, this ratio drops by 50% at E10.5 and by >95% (~48-fold 
reduction) at E11.5 (Figure 9C).  It is important to note all embryos collected for 
these analyses appeared healthy and viable, as described in the Supplemental 
Methods section.  In other words, the Dbh-/- embryos used throughout this study 
were phenotypically indistinguishable from controls at the time of isolation.  
These results demonstrate that Dbh-/- embryos exhibited an energy deficit 
beginning around E10.5 that rapidly became much more severe within 24h 
(E11.5). 
To determine if the observed energy depletion was due to the absence of 
β-adrenergic stimulation, we attempted to rescue the phenotype by providing ISO 
in the maternal drinking water beginning at E8.5.  When the experiment was 
repeated under these conditions, the ATP deficits disappeared (Figure 9D).  We 
observed a 1.8-fold increase in ATP concentrations at E10.5 and a 4.5-fold 
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increase in E11.5 Dbh-/- ATP concentrations after ISO treatment compared to 
those observed without the addition of ISO.  These results demonstrate that β-
adrenergic stimulation was effective at preventing the energy loss resulting from 
adrenergic deficiency in developing mouse embryos. 
Influence of adrenergic hormones on embryonic carbohydrate and lipid 
metabolism 
Carbohydrate metabolism is the principle source of energy for the 
developing heart prior to birth (Cox and Gunberg, 1972; Ellington, 1987; Shepard 
et al., 1970).  To determine if key carbohydrate metabolites were altered in 
adrenergic-deficient embryos, we measured glucose, glycogen, and lactate 
concentrations in embryos isolated at E10.5 and E11.5 (Table 4).  No significant 
differences were observed in the concentrations of these carbohydrate 
metabolites at these ages. However, lactate concentrations appeared slightly 
elevated, on average, in adrenergic-deficient embryos at both E10.5 and E11.5, 
but these differences were also not statistically significant.  Glycogen 
concentrations trended lower in the deficient group, but the results were variable 
and again not found to be significantly different.  The biochemical results for 
glycogen were corroborated by image analysis of glycogen granules from 
transmission electron microscopy (TEM) micrographs, which showed a similar 
insignificant downward trend in glycogen granules at E11.5 for the adrenergic-
deficient group (Table 4).  We also measured free fatty acid concentrations and 
lipid droplets, but found no significant differences in these either, though there 
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was a downward trend in the deficient group for lipid droplets, which were 
predominantly located in the liver at these stages of development.  Despite these 
trends, steady-state levels of free fatty acids as well as glucose, glycogen, and 
lactate were relatively unchanged (no significant differences) in adrenergic-
deficient embryos compared to age-matched littermate controls at E10.5 and 
E11.5 (Table 4).   
When we examined the rate of glycolysis, however, significant differences 
were observed.  To perform these measurements, we isolated and cultured 
whole beating hearts from E10.5-E11.5 Dbh-/- and littermate controls, and 
recorded the extracellular acidification rate (ECAR) at various intervals over a 40-
min period.  Similar beating rates were observed in the adrenergic-competent 
and deficient samples at both ages (Figure 9).  At E10.5, there was little 
difference in ECAR from adrenergic-deficient and control samples over the entire 
40-mins (Figure 10A).  At E11.5, however, adrenergic-deficient and control 
ECARs were similar initially, but began to decline in the adrenergic-deficient 
group after about 10-mins and continued to decline further over the next 30-mins 
such that it was less than half the initial rate by 40-mins (Figure 10B).  This 
decline was prevented by the addition of ISO in the maternal drinking water 
(Figure 10C).  These results suggest that glycolysis was compromised in 
adrenergic-deficient hearts by E11.5. 
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Oxygen consumption rate (OCR) decrease due to absence of β-adrenergic 
stimulation 
Mitochondria begin to play an increasingly important role in the heart at 
these early embryonic stages of development.  To determine if adrenergic 
hormones influence mitochondrial respiration, oxygen consumption rates (OCRs) 
were measured in beating embryonic hearts isolated and cultured from E10.5 
and E11.5 adrenergic-deficient and age-matched littermate control samples.  At 
both ages, OCR was significantly lower in the adrenergic-deficient hearts over a 
35-min period as shown in Figure 12 (panels A & B).  To confirm the oxygen 
consumption was from mitochondrial function, we administered rotenone (0.5 
µM) and antimycin A (2 µM) to adrenergic-competent isolated hearts to block 
complexes I and III, which significantly decreased the overall OCR (Figure 13).  
OCR increased similarly in adrenergic-deficient and competent hearts between 
E10.5 and E11.5 (compare panels A & B, Figure 12), but the adrenergic-deficient 
group nevertheless continued to lag significantly below the control group through 
E11.5.  It is important to note that hearts appeared similar and were beating 
spontaneously at comparable slow but steady rates in both adrenergic-deficient 
and competent hearts during the ex vivo culture period.  Thus, despite the lack of 
any clear differences in outward appearance or behavior, adrenergic-deficient 
hearts consumed oxygen at significantly lower rates than control hearts, thereby 
indicating their ability to carry out OXPHOS was significantly and substantially 
decreased relative to adrenergic-competent controls.  To verify this effect was 
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due to the absence of adrenergic hormones, we show that rescue with ISO 
restored OCRs in adrenergic-deficient hearts (Figure 12 panels C & D). 
Mitochondrial biogenesis not affected by the loss of adrenergic-hormones 
In theory, the lowered OCR and ATP/ADP could be due to fewer 
mitochondria resulting from compromised mitochondrial biogenesis in 
adrenergic-deficient hearts.  To test this hypothesis, we measured expression of 
key mitochondrial biogenesis genes; however, no significant alterations in mRNA 
for Pgc-1α (p=0.58), Tfam (p=0.47), and Sirt1 (p=0.65) were found in E10.5 
isolated hearts when normalized to the housekeeping gene Gapdh (Figure 14A).  
Similar results were found at E11.5.  We also measured mitochondrial DNA 
(mtDNA) content present in adrenergic-deficient and control hearts, but no 
significant differences were observed (Figure 14B).  Although not significant, 
there was a small apparent increase in mtDNA at E10.5, which may be related to 
the similar upward trend seen in Pgc-1α from this group (compare Figure 14A 
and 14B).  These results suggest that mitochondrial biogenesis is not likely a 
limiting factor in adrenergic-deficient embryos at these early stages. 
Adrenergic-deficient myocytes have intact mitochondrial membranes 
The decreased OCR in adrenergic-deficient hearts suggests that 
mitochondrial function may be impaired.  To properly function, mitochondria must 
maintain membrane potentials sufficient to drive the proton gradients necessary 
for OXPHOS in their inner membrane space.  The fluorescent dye JC-1 can 
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distinguish between mitochondria with intact membranes and those with 
compromised membrane potentials via differential fluorescence emissions(Reers 
et al., 1991).  For example, red fluorescence (~590 nm) detects aggregates and 
is indicative of healthy intact membranes, while green fluorescence (~529 nm) 
detects monomers associated with perturbed mitochondrial potentials.  We 
employed JC-1 staining with flow cytometry in combination with laser-scanning 
confocal fluorescence microscopy to assess mitochondrial membrane potential 
integrity in cardiomyocytes isolated from E10.5 and E11.5 adrenergic-competent 
and deficient hearts.  Flow cytometry for red (aggregates) and green (monomers) 
showed no difference between adrenergic-deficient and control samples at E10.5 
(Figure 15A) or E11.5 (Figure 15C).  Quantification of the stained primary 
cardiomyocyte culture showed a red to green ratio of 3.4 ± 0.7; n=9 in the E10.5 
deficient samples and 3.1 ± 0.6; n=9 in controls (Figure 15B).  Similar results 
were observed in the E11.5 primary cardiomyocyte cultures with the red to green 
ratio of 3.4 ± 1.3; n=4 in the deficient group and 2.5 ± 0.8; n=4 in the control 
group (Figure 15D).  Representative mitochondrial staining with JC-1 is shown in 
Figure 15E for adrenergic-competent and deficient myocytes isolated from E11.5 
hearts.  Despite the fact there were no significant differences in the ratio of 
red/green staining in these specimens, the mitochondrial staining pattern in the 
adrenergic-deficient group appeared to be less densely clustered and less well-
organized within myocytes than those typically found in age-matched adrenergic-
competent littermates, indicating there may be structural abnormalities in 
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mitochondria from adrenergic-deficient embryos.  At this resolution, however, it 
was difficult to determine if there were truly structural anomalies in the 
mitochondria, so we employed transmission electron microscopy (TEM) for these 
evaluations as described below. 
Mitochondrial morphology altered in adrenergic-deficient hearts 
To obtain a more detailed view and assessment of mitochondrial structure 
in adrenergic-deficient and control embryonic hearts, we analyzed cardiac tissue 
specimens using TEM.  Our results show that mitochondria within E10.5 
adrenergic-deficient myocardium were enlarged and appeared swollen (Figure 
16B) relative to adrenergic-competent controls (Figure 16A).  Similar results were 
observed in E11.5 adrenergic-deficient hearts, demonstrating elongated 
mitochondria (Figure 16F) compared to adrenergic-competent samples (Figure 
16E).  Additionally, multiple mitochondria showed a branching and swollen 
appearance (Figure 16C and 16G arrowheads).  Tracings of the abnormal 
shaped mitochondria observed in adrenergic-deficient hearts are shown for 
E10.5 (Figure 16D) and E11.5 hearts (Figure 16H).  Like E10.5 adrenergic-
deficient samples, E11.5 mutants had a significantly (p<0.05) decreased number 
of mitochondria per micrograph as compared to E11.5 adrenergic-competent 
hearts (Table 5).  While there was a decreased number of mitochondria, the 
length of those present was considerably increased (p<0.0001) in the adrenergic-
deficient samples versus controls (Table 5).  Consequently, increased (p<0.001) 
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overall mitochondrial surface area was observed within myocytes for the 
adrenergic-deficient samples when compared to controls (Table 5).  These 
results clearly show that mitochondrial structure is significantly altered in 
adrenergic-deficient embryos.  On average, the mitochondria were longer, had 
greater surface area, and displayed more abnormal shapes such as branch 
points, curvatures, and budding bulges in their membranes compared with their 
control counterparts.   
Discussion 
Anaerobic glycolysis is the predominant mode of metabolism of the heart 
during early embryonic development, but aerobic mitochondrial metabolism 
becomes an increasingly important and essential mode of energy production at 
late embryonic to early fetal stages of development (Cox and Gunberg, 1972; 
Ellington, 1987; Shepard et al., 1970).  For example, classic studies showed that 
isolated embryonic rat hearts utilized glycolytic mechanisms through E11; 
however, glycolysis was not sufficient to maintain maximal heart rates at E12 or 
E13 (Cox and Gunberg, 1972).  Further, energy metabolism was unaffected by 
the presence of oxygen at E11 in the rat, but was significantly and progressively 
elevated by oxygen in E12 and E13 hearts.  This embryonic-shift in metabolic 
capability between E11-E12 in the rat roughly corresponds to the end of the 
organogenesis period of embryonic development and the beginning of fetal 
development.  In the mouse, the equivalent stages of development are 
67 
 
approximately E9.5-E10.5 (Theiler, 1972).  It is at this embryonic/fetal juncture 
when metabolic deficiencies first become apparent in Dbh-/- mouse embryos, 
which lack the ability to produce the adrenergic hormones, NE and EPI.  
At E9.5, there was no discernible difference in ATP or ADP concentrations 
in adrenergic-deficient and control embryos, but ATP/ADP ratios began to 
decline at E10.5 and much more dramatically so at E11.5 in adrenergic-deficient 
embryos.  It seems unlikely this decline in ATP/ADP can be fully ascribed to 
glycolysis since no significant differences were observed in key glycolytic 
metabolites including glucose, pyruvate, and lactate at E10.5 or E11.5.  In 
addition, glycolytic rates (ECAR) were virtually identical at E10.5 in adrenergic-
deficient and control embryos.  By E11.5, however, ECAR began to decline in the 
adrenergic-deficient group, indicating that glycolytic rate was compromised.  The 
decline was not apparent immediately, but developed over a 15-30 min period, 
and could be prevented by supplying the β-agonist, isoproterenol.  At present, it 
is not yet clear how β-adrenergic stimulation influences glycolytic rates in the 
embryo.  Potential targets include Protein Kinase A (PKA)-mediated 
phosphorylation of glycolytic and glycogenolysis enzymes (Krebs and Fischer, 
1956).  Further study is required to determine which enzymes or other factors 
may be influenced by adrenergic hormones in the embryonic condition. 
As we have shown, OCR was also significantly decreased in adrenergic-
deficient hearts at E10.5 and E11.5 relative to littermate controls.  These results 
indicate that aerobic metabolism was compromised in these embryos.  In fact, it 
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appeared that basal OCRs in adrenergic-deficient hearts lagged about a day 
behind adrenergic-competent hearts, and were only about 50% of control levels 
at E10.5 and E11.5.  These effects were extinguished by supplying isoproterenol 
in the maternal drinking water, thereby indicating the absence of β-adrenergic 
stimulation was responsible for the declining OCRs in Dbh-/- embryos.  These 
results suggest that oxidative phosphorylation was impaired in adrenergic-
deficient embryos.   
Consistent with these observations, we found that mitochondrial structure 
was significantly altered in adrenergic-deficient embryos.  TEM analyses showed 
that mitochondria were enlarged and more frequently displayed branching or 
budding membranes in adrenergic-deficient hearts at E10.5 and E11.5.  Despite 
the abnormal mitochondrial morphology in these hearts, the membranes 
appeared to be intact with well-formed cristae.  Further, no significant alterations 
in red/green fluorescence ratios were observed following application of the 
mitochondrial membrane potential-sensitive dye, JC-1, in adrenergic-deficient 
hearts compared with controls.  These findings suggest that although the 
mitochondria were larger and abnormally shaped, the observed structural 
changes may represent compensatory mechanisms to try and increase ATP 
production in energy-starved Dbh-/- hearts (Gomes et al., 2011; Mao et al., 2013).  
Indeed, enlarged mitochondria have been associated with enhanced metabolic 
output while smaller fragmented mitochondria have generally been associated 
with decreased metabolic output (Knott et al., 2008; Palorini et al., 2013; Tasseva 
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et al., 2013).  In the present study, however, we observed enlarged mitochondria 
with apparent decreased metabolic output.  The phenomenon of elongated 
mitochondria with diminished function has been demonstrated previously in other 
models of mitochondrial dysfunction (Benard et al., 2007; Chen et al., 2003; 
Mortiboys et al., 2008). 
We speculated the Dbh-/- embryos may be starved for substrate 
metabolites, but as indicated above, little change was observed in key 
carbohydrate or lipid substrates.  This result was not entirely unexpected since 
glucose is known to pass freely from maternal blood supply to the embryo 
(Takata et al., 1994).  These results suggest that metabolic substrates did not 
appear to be depleted in adrenergic-deficient embryos.  It is possible, however, 
the rate of substrate transport into cells and/or inner membrane space of 
mitochondria could be a limiting factor in the embryos, and this will likely be an 
important target for future investigations.  The inability of the embryo to increase 
nutrient supply and subsequently increase metabolic rate provides an 
explanation for the differences observed in the embryonic versus adult Dbh-/- 
mice, which compensate by increasing food intake and basic metabolic rates 
through mechanisms that are not fully understood (Thomas and Palmiter, 1997).   
 The pathophysiology of adult heart failure is commonly characterized by 
mitochondrial dysfunction, indicated by decreased energy production (Ingwall 
and Weiss, 2004; Ventura-Clapier et al., 2004; Ventura-Clapier et al., 2011).  
However, in the Dbh-/- embryos the signs of energy starvation are seen before 
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any outward precursor of heart failure.  Indeed, metabolic deficiencies were 
observed in Dbh-/- embryos that were otherwise phenotypically indistinguishable 
from adrenergic-competent controls at the time of isolation in terms of size, 
morphology, color, texture, and cardiac beating activity.  These results suggest 
that metabolic defects likely contribute to the subsequent heart failure and 
embryonic lethality in this model. 
 The results presented here open the door for exploration of the 
mechanisms responsible for the observed energy deficits in embryos lacking the 
ability to produce adrenergic hormones.  Potential targets for adrenergic-
mediated regulation of aerobic metabolism include, but are not limited to, 
electron transport chain enzymes in mitochondria such as complex I or IV, which 
have both been shown to be substrates for PKA-mediated phosphorylation (Acin-
Perez et al., 2011; De Rasmo et al., 2011; Papa et al., 2012).  Alternatively, 
proteins that regulate mitochondrial structure by promoting fission or fusion (Drp1 
and Mfn2) have also been shown to be subject to PKA-mediated phosphorylation 
(Chang and Blackstone, 2007; Cribbs and Strack, 2007; Zhou et al., 2010), and 
alterations in their activities may also be crucial for mitochondrial function in 
these embryos.  Yet other avenues for investigation here include ATP utilization 
rates (Ingwall, 2006; Luptak et al., 2005), the creatine kinase system (De Sousa 
et al., 1999; Nascimben et al., 1996), other subunits of the electron transport 
chain (Chung et al., 2007; Spitkovsky et al., 2004), and regulation of the closing 
of the mitochondrial transition pore, which naturally occurs at similar stages of 
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development (~E10.5) in embryonic mouse hearts (Drenckhahn, 2011; Halestrap 
and Pasdois, 2009; Hom et al., 2011).  The G protein-coupled receptor kinase 2 
(GRK2) is another attractive target since it is activated by β-adrenergic 
stimulation, is essential for heart development and embryonic survival, and 
appears to be an important signaling intermediary in the regulation of 
mitochondrial metabolism (Chen et al., 2013; Fusco et al., 2012; Jaber et al., 
1996; Lymperopoulos et al., 2013).  Future experiments are needed to 
distinguish between these various possibilities. 
 In summary, we have shown that adrenergic hormones fulfill a critical 
developmental role by serving to provide the growing embryo with sufficient 
chemical energy in the form of ATP to enable successful transition from 
embryonic to fetal stages.  Further, our results demonstrate that adrenergic 
hormones are necessary to maintain sufficient ATP/ADP, ECAR, and OCR 
during late periods of embryonic development in preparation for the transition to 
the fetal period.  The discovery of these influential regulatory connections 
between adrenergic hormones and embryonic energy metabolism opens new 
paths for the study of cardiovascular development that could give rise to novel 
therapeutic targets and strategies for treating congenital heart defects (Chin et 
al., 2012; Krebs et al., 2011) as well as adult forms of heart disease. 
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Tables 
 
 
 
Table 3 ATP, ADP, and ATP/ADP ratio values of adrenergic-deficient and 
control embryos.  
 
 
Values obtained from standard curve of known ATP and ADP concentrations.  
Data are represented as mean±SEM. *, p<0.05; **, p<0.01; ***, p<0.001 
 
  
[ATP]
(nmol/mg 
protein)
[ADP]
(nmol/mg 
protein)
ATP/ADP 
Ratio
(AU)
Number
of 
samples
E
9
.5 Competent 40.6 ± 10.7 19.8 ± 6.6 3.9 ± 1.2
12
Deficient 32.4 ± 8.3 10.8 ± 2.9 3.8 ± 1.2
6
E
1
0
.5 Competent 26.8 ± 3.1 9.1 ± 1.9 5.1 ± 1.0
13
Deficient 19.5 ± 7.3 9.9 ± 4.1 2.6 ± 0.8
5
E
1
1
.5 Competent 7.6 ± 0.5 0.8 ± 0.06 9.4 ± 1.3
8
Deficient 1.0 ± 0.4*** 4.3 ± 1.3** 0.2 ± 0.03***
4
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Table 4 Carbohydrate and Lipid Metabolite Concentrations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values obtained from standard curve of known concentrations.  Data are 
represented as mean±SEM. 
  
 
E10.5 E11.5 
 
 
Competent 
 
Deficient 
 
p-
value 
 
Competent 
 
Deficient 
 
p-
value 
 
 
Glucose 
(nmol/mg 
protein) 
 
313±17 
n=10 
 
260±26 
n=9 
 
0.09 
 
 
436±27 
n=8 
 
421±44 
n=7 
 
0.77 
 
Glycogen 
(nmol/mg 
protein) 
 
5.8±1.4 
n=4 
 
7.5±1.5 
n=4 
 
0.45 
 
9.9±6.5 
n=4 
 
4.3±2.2 
n=3 
 
0.51 
 
Glycogen 
Granules 
(% per nm2) 
 
5.0±0.6 
n=32 
 
6.2±0.9 
n=46 
 
0.30 
 
4.8±1.0 
n=18 
 
3.3±0.7 
n=23 
 
0.20 
 
Lactate 
(nmol/mg 
protein) 
 
250±50 
n=6 
 
422±107 
n=6 
 
0.17 
 
293±37 
n=6 
 
416±78 
n=6 
 
0.18 
 
Lipid (liver) 
Droplets 
(per sq. mm) 
 
5015±677 
n=10 
 
3528±416 
n=14 
 
0.06 
 
5866±598 
n=16 
 
3988±869 
n=16 
 
0.09 
 
Free Fatty Acids 
(nmol/mg 
protein) 
 
1.6±0.2 
n=10 
 
1.5±0.2 
n=10 
 
0.86 
 
1.5±0.1 
n=8 
 
1.5±0.3 
n=7 
 
0.92 
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Table 5 Quantification of transmission electron microscopy.  
 
 
Data are expressed mean ± sem.  *, p<0.05; **, p<0.01; ***, p<0.001 
  
 
  E10.5  
Adrenergic- 
Competent 
E10.5  
Adrenergic-
Deficient 
E11.5 
Adrenergic-
Competent 
E11.5 
Adrenergic-
Deficient 
Number per 17.5 
µm2 
  
12.3 ± 0.5 
n=59  
  
10.4 ± 0.4** 
n=103 
  
13.9 ± 1.1 
n=38 
 
11.0 ± 0.7* 
n=38 
Length (nm)  
715.9 ± 13.7 
n=701  
  
775.9 ± 14.6** 
n=1074 
  
637.5 ± 17.4 
n=529 
 
888.5 ± 27.9*** 
n=418 
Surface Area 
(µm2) 
 
245 ± 10.4 
n=171  
  
324.9 ± 21.1*** 
n=140 
  
204.8 ± 10.6 
n=166 
 
362.8 ± 28.7*** 
n=127 
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Figures 
 
 
Figure 9 ATP, ADP and ATP/ADP measurements in adrenergic-deficient 
embryos compared to controls. 
(A) ATP, (B) ADP, and (C) ATP/ADP ratio measurements at E9.5, E10.5, and 
E11.5 in adrenergic-competent (black bars) and adrenergic-deficient littermates 
(white bars).  (D) ATP measurements at E10.5 (n≥10) and E11.5 (n≥4) in 
adrenergic-deficient embryos with and without isoproterenol.  Fold-change 
calculations were generated from steady-state ATP and ADP concentrations.  *, 
p<0.05; **p<0.005; ***, p<0.001. 
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Figure 10 Beating rates of embryonic mouse hearts after 24-hrs of ex vivo 
culture. 
Data are presented as mean ± SEM. 
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Figure 11 Effects of adrenergic-deficiency on glycolytic ECAR. 
(A-B) ECAR in E10.5 and E11.5 adrenergic-competent (closed circles) and 
deficient (open squares) isolated beating hearts.  For E10.5 adrenergic-
competent, n= 15 and deficient, n=9.  For E11.5 adrenergic-competent, n=28 and 
deficient, n=8.  (C) ECAR fold-change at 40-min between adrenergic-competent 
(black bars) and deficient (white bars) E11.5 isolated hearts with and without 
isoproterenol in maternal drinking water.  Mean ± SEM values at the final (40-
min) timepoint are shown. *, p<0.05. 
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Figure 12 Effects of adrenergic-deficiency on OCR in isolated embryonic 
hearts. 
(A-B) OCR in E10.5 and E11.5 adrenergic-competent (closed circles) and 
deficient (open squares) hearts.  Numerical values in the columns refer to the 
number (n) of samples analyzed.    For E10.5 adrenergic-competent, n= 15 and 
deficient, n=9.  For E11.5 adrenergic-competent, n=20 and deficient, n=9.  (C-D) 
OCR fold-change at 15-min between adrenergic-competent (black bars) and 
deficient (white bars) E10.5 and E11.5 isolated hearts with and without 
isoproterenol.  Data are represented as mean ± SEM. *, p<0.05. 
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Figure 13 OCR is due to mitochondrial function in isolated embryonic 
hearts. 
(A) OCR E10.5 (circles) and E11.5 (squares) adrenergic-competent hearts 
treated with rotenone and antimycin A.  (B) OCR in E10.5 (n=9) and E11.5 (n=7) 
adrenergic-competent hearts before (black bars) and after (lined bars) rotenone 
and antimycin A treatment.  Data are represented as mean±SEM. *, p<0.05; ***, 
p<0.001  
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Figure 14 Mitochondrial biogenesis gene expression and mtDNA content in 
adrenergic-deficient versus control hearts. 
(A) Fold-change of key mitochondrial biogenesis genes between adrenergic-
competent and deficient mRNA from E10.5 (n=5) and E11.5 (n=6) hearts as 
measured by quantitative RT-PCR analysis.  (B) Mitochondrial DNA (mtDNA) 
content fold-change between E10.5 and E11.5 adrenergic-competent (black 
bars) and deficient (white bars) hearts. Numerical values in the columns refer to 
the number (n) of samples analyzed. 
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Figure 15 Analysis of mitochondrial membrane potentials in adrenergic-
deficient and control myocytes using flow cytometry and fluorescence 
microscopy with JC-1 dye. 
(A and C) Representative scatter plots of flow cytometry with red and green 
fluorescence from JC-1 dye in adrenergic-deficient and adrenergic-competent 
E10.5 and E11.5 embryonic primary cardiomyocytes.  Adrenergic-competent 
samples (red) and adrenergic-deficient samples (blue) in histogram overlay.  (B 
and D) Ratio of red/green fluorescence in E10.5 and E11.5 adrenergic-
competent (white bars) and deficient (black bars) samples.  Numerical values in 
the columns refer to the number (n) of samples analyzed.  (E) Representative 
scanning laser confocal microscopy of JC-1 dye in E11.5 primary 
cardiomyocytes.  Scale bar, 10 μm. 
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Figure 16 Ultrastructural analysis of mitochondria in adrenergic-deficient 
and control hearts following evaluation of TEM images. 
Mitochondrial morphology in adrenergic-competent and deficient E10.5 (compare 
A and B) and E11.5 (compare E and F) myocytes.  (C and G) Branched 
(arrowheads) and swollen mitochondria in adrenergic-deficient samples.  (D and 
H) Representative tracings of abnormally shaped mitochondria in adrenergic-
deficient samples.  (I) Number of mitochondria per defined micrograph area (17.5 
µm2) in E10.5 and E11.5 adrenergic-competent (black bars) and deficient (white 
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bars) samples.  (J) Mitochondrial length in E10.5 and E11.5 adrenergic-
competent (black bars) and deficient (white bars) samples.  (K) Surface area of 
mitochondria in E10.5 and E11.5 adrenergic-competent (black bars) and deficient 
(white bars) samples.  Abbreviations: m=mitochondria; n=nucleus.  *, p<0.05; **, 
p<0.01; ***, p<0.001.  Scale bar= 500 nm. 
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CHAPTER FOUR:  
ECHOCARDIOGRAPHIC ANALYSIS OF LEFT VENTRICULAR 
FUNCTION IN STRESS-CHALLENGED AGED MICE: EFFECTS OF 
GENDER (SEX) AND MENOPAUSE 
Abstract 
To investigate age, sex, and menopausal differences left ventricular (LV) 
function was evaluated using high-resolution ultrasound in age-matched male, 
pre- and post-menopausal female mice hearts at from nine months to 21 months 
old at baseline and in response to epinephrine and immobilization stress.  We 
found a more robust response to epinephrine stimulation in males at nine months 
compared to females.  After the induction of menopause, similarities were found 
between males and menopausal females with regards to end systolic and 
diastolic volumes, fractional shortening and cardiac output.  This trend persisted 
when the same group of mice underwent immobilization stress.  These data 
demonstrate that biological sex and menopause have significant influence on LV 
function in response to various stressors in mice.  Lastly, we found the 
distribution of adrenergic cell population was void in the aged cycling female 
heart and only after the induction of menopause are adrenergic cells observed in 
the left heart.  This indicates differential adrenergic cell populations are present in 
male versus females and pre- versus post-menopausal females. 
  
94 
 
Introduction 
Heart failure (HF) afflicts populations across the globe with an annual 
mortality rate of nearly 10% of the population.  Male HF patients often exhibit a 
reduced ejection fraction (EF) compared to a preserved EF in female patients 
(Hogg et al., 2004; Regitz-Zagrosek et al., 2010).  Reduction in EF is correlated 
with an overall drop in heart function and, ultimately, survival.  This interesting 
gender difference has been highly studied in the clinical settings (Cleland et al., 
2003; Regitz-Zagrosek et al., 2007) and in animal models (Du, 2004); however, 
mechanistic regulation of these observed gender differences in relation to the 
progression and prognosis of heart failure remains obscure.  These studies 
demonstrate a need for divergent treatment of male versus female heart failure 
patients.   
Additionally, stress-induced cardiomyopathies, such as Takotsubo 
cardiomyopathy, predominantly afflict post-menopausal women (greater than 
82% of such cases) who have experienced a sudden emotional shock (H. Sato, 
1990).  These women display left ventricular (LV) dysfunction characterized by 
hypo- or a-kinetic regions, particularly near the apex and often have elevated 
plasma catecholamines, and are at high risk of arrhythmia and sudden cardiac 
death if left untreated (Kume et al., 2008; Wittstein et al., 2005; Yoshida et al., 
2007).  At present, it is not entirely clear why only specific regions of the LV are 
primarily affected, nor is it understood why postmenopausal women are 
particularly susceptible to these types of stress cardiomyopathies (Baker, 2014).   
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The effects of age, sex and menopausal status on cardiovascular function 
have been investigated individually; however these three important factors 
contributing to left ventricular function have not been looked at together, nor in 
response to stress stimuli. Additionally, very few studies have been conducted in 
vivo.  Myocardial response to adrenergic hormones has been extensively 
investigated in vitro and the effects of sex and menopause have been 
incorporated into these types of studies (Luczak and Leinwand, 2009; McIntosh 
et al., 2011; Schwertz et al., 1999; Vizgirda et al., 2002). 
Recent work has shown distribution of historical and/or active intrinsic 
adrenergic derived myocardium in young adult mice follows a similar pattern to 
that seen in regions of the left heart most commonly affected in stress induced 
cardiomyopathy patients (Osuala et al., 2011).  These areas include the base, 
mid and apical sections of the left heart.  In addition, Kume et al. showed 
increased catecholamines concentrations in the apex as compared to the base in 
five confirmed cases of Takotsubo cardiomyopathy (Kume et al., 2008).  These 
results suggest differential local catecholamine concentrations in apical versus 
basal regions of the left heart, likely originating from the intrinsic adrenergic cells 
located in these regions (Baker, 2014).  
We hypothesized there are inherent differences between in vivo left 
ventricular function due to sex, age, and menopausal status and tested this 
hypothesis by injecting epinephrine before and after menopause induction in 
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mice while performing high-resolution echocardiography.  Further, to recapitulate 
an emotional stress paradigm, immobilization stress was conducted and cardiac 
function was monitored using echocardiography.  Upon conclusion of all 
functional studies, the hearts were then excised and viewed for histological 
distribution of adrenergic myocardium. 
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Materials and Methods 
Mice 
All procedures and handling of mice were conducted in accordance with The 
University of Central Florida Institutional Animal Care and Use Committees.  
PnmtCre/Cre and ROSA26βgal/βgal mice were bred and maintained as previously 
described.  PnmtCre/Cre and ROSA26βgal/βgal were mated and resulting offspring 
(Figure 17) were aged to 9 months before the first ultrasounds were performed. 
Epinephrine Injections and Echocardiography 
Mice were anesthetized with 2% isoflurane for duration of epinephrine injection 
studies.  Body temperature was maintained between 36-37ºC using a heated 
platform and monitored with rectal probe.  Transthoracic echocardiography was 
performed using a Vevo® 2100 (Visual Sonics, Toronto, Canada) system 
equipped with a high frequency 40 MHz transducer.  Recordings were conducted 
every 5 min for 20 min to avoid any artifact from isoflurane.  Intraperitoneal 
epinephrine injections were administered at a dose of 50 mg/kg body weight.  
Recordings continued for 40 min at 5 min intervals.  Calculations were made 
from recordings taken directly prior to injection and at peak heart rate after 
injection. 
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Immobilization and Echocardiography 
Mice were anesthetized with 2% isoflurane for hair removal and baseline 
recordings.  Body temperature was maintained using an external heating pad.  
Mice were restrained in the supine position with limbs secured in place with 
perforated tape.  After baseline recordings anesthesia was removed and mice 
were allowed to become fully conscious.  Transthoracic echocardiography was 
performed using a Vevo® 2100 (Visual Sonics, Toronto, Canada) system 
equipped with a high frequency 40 MHz transducer.  Recordings were taken at 
15 min, 1 hr, and 2 hr timepoints.  Calculations were made from recordings taken 
at baseline and 2 hr. 
Menopause Induction 
Menopause was chemically induced using 4-vinylcyclohexane diepoxide (VCD) 
(160 mg/kg/day) intraperitoneal injections for 15 consecutive days as previously 
described (Hoyer and Sipes, 2007).  Vehicle control (peanut oil) injections were 
performed in parallel. 
Vaginal Cytology 
Menopause was confirmed by persistent diestrus for 5 consecutive days using 
vaginal cytology in both VCD and vehicle control groups.  Briefly, sterile normal 
saline (20 µL) was flushed in vaginal cavity and collected on microscope slide 
daily.  Slides were examined using 10X objective light microscopy using a Leica 
DM2000 microscope with a Leica DFC295 camera for distribution patterns of cell 
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type present.  Upon examination of estrous cycle of control injection females, 
forty percent of the mice were determined to have undergone a natural 
menopause.  Five days of persistent diestrus was classified as menopausal, if a 
mouse cycled from proestrous to estrus to metestrus to diestrus then back to 
proestrus, this indicated a typical 4 day estrus cycle and that mouse was 
classified as cycling.  Diestrus is characterized by primarily the presence of 
leukocytes, proestrus by nucleated epithelial cells, estrus by cornified anucleated 
cells, and metestrus by a combination of all three cell types. 
Corticosterone Measurements 
Plasma corticosterone levels were measured following manufacturer’s protocol 
using an ELISA (rat/mouse) kit from IBL-America (Minneapolis, MN). 
Histological Preparations 
Pnmt+/Cre ROSA26+/βgal mice aged 9 months and 21 months were sacrificed by 
cervical dislocation or swift decapitation.  The heart was rapidly removed and 
retrogradely perfused through the aorta with phosphate-buffered saline then 2% 
paraformaldehyde.  Adrenal glands were removed and processed similarly as 
hearts.  Tissue was then placed in 2% paraformaldehyde for 24 hr at 4ºC then 
moved to 30 % sucrose with 0.02% sodium azide for storage.  For sectioning the 
hearts and adrenal glands were embedded in Tissue-Tek® OCT compound (EM 
Sciences, Hatfield, PA) and sectioned at 12 micron using a Leica (CM1850 
cryostat) at -20-24ºC, sections were stored at -20 ºC for subsequent staining.  
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Tissue sections were stained for β-galactosidase activity as previously described.  
Images were taken using a Leica L2 microscope and Leica EC3 camera and 
quantification of blue pixels were determined using Adobe Photoshop magic 
wand tool. 
Statistics 
Data are expressed as mean ± S.E.M. Student t-tests were performed to 
compare means between two groups and ANOVA performed between three 
groups, with p < 0.05 required to reject the null hypothesis.   
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Results 
Pre-menopausal EPI Challenge 
At 9 months of age male and female mice were subjected to baseline 
echocardiography to assess LV function.  After 20 mins epinephrine (EPI, 50 
mg/kg) was injected into the intraperitoneal cavity.  Baseline heart rate was 
significantly higher in the female mice group as compared to the males, however, 
the males responded more robustly to the EPI than females (Figure 18A).  
Baseline left ventricular end diastolic and systolic volumes were significantly 
greater in the males as compared to females at baseline (Figure 18B and C), 
most likely due to the larger size of males compared to age matched females.  
Notably, a higher percent change in end diastolic and systolic volumes was seen 
in males as compared to females after EPI injections (Figure 18F).  Stroke 
volume was also increased in males as compared to females at baseline and 
after EPI injections (Figure 18D).  A significant increase in stroke volume after 
EPI injection was also observed in males as compared to females (Figure 18F).  
Lastly, cardiac output was significantly higher in males than females before and 
after EPI injections, with both groups displaying a similar increase after the 
injection (Figure 18E and F).  Complete echocardiographic measurements at 
baseline and response to EPI are shown in Table 6.  These results show that 
males have a more robust response to EPI as compared to age matched 
females. 
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Post-menopausal EPI Challenge 
After induction and confirmation of menopause, EPI injections were 
repeated in males and females, only the female group was divided into pre-
menopausal (i.e. cycling) and post-menopausal (i.e. non-cycling) subgroups.  At 
baseline there were no differences in heart rate between the three groups (Figure 
19A).  After the injection of EPI significant differences were observed between 
the pre-menopausal females, post-menopausal females and male heart rates 
(Figure 19A), though the percent increases after EPI injections were not different 
between the three groups (Figure 19F).  In addition, end systolic and diastolic 
volumes were significantly different between the three groups at baseline, though 
end diastolic volumes varied between the groups after EPI injections (Figure 19B 
and C).  Stroke volumes were similar between the groups at baseline and only 
after EPI injections were differences observed between males, cycling and 
menopausal females (Figure 19D).  A similar pattern was observed with cardiac 
output, demonstrating differential effects to EPI measured between the three 
groups, but not at baseline (Figure 19E).  Complete echocardiographic 
measurements at baseline and response to EPI are shown in Table 7. 
Age Effects 
Next, we investigated the effects of age from 9 months to 21 months in 
males and females when stress was induced with EPI injections.  Heart rate was 
not significantly different when comparing males and females at nine months 
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versus eighteen months of age before and after EPI injections (Figure 20A and 
21A).  End systolic (p<0.001) and diastolic (p<0.05) volumes increased 
significantly only in males between nine and eighteen months, after EPI these 
differences were no longer measured (Figure 20B and C).  Stroke volume was 
significantly higher in males after aging (Figure 20D).  However, it was drastically 
decreased in females at eighteen months compared to stroke volume at nine 
months (Figure 21D).  Cardiac output was highly similar between the ages in 
both genders (Figure 20E and 21E). 
Sex and Menopausal Status in Response to Immobilization Stress 
Immobilization stress was utilized to recapitulate the emotional stress that 
is typically a precipitating factor in stress-induced cardiomyopathies.  Baseline 
heart rates were not different between males, cycling and menopausal females 
(Figure 22A).  However, after 2 hours of immobilization stress (IMO) ANOVA 
statistics determined a significant (p<0.05) variation between the three groups.  
End systolic volume showed no statistically significant differences (Figure 22B) 
and end diastolic volume demonstrated variability only after IMO stress (Figure 
22C).  Stroke volume showed no difference at baseline however, after IMO 
cycling females had significantly lowered values as compared to males and 
menopausal females, which were not different from one another (Figure 22D).  
Similarly, cardiac output was significantly different amongst the three groups at 
baseline with cycling females have the lowest values (Figure 22E).  All three 
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groups had similarly high blood corticosterone levels as compared to unstressed 
control mice (Figure 23), thereby confirming the mice were clearly stressed 
physiologically.  Complete echocardiographic measurements at baseline and 
response to EPI are shown in Table 8. 
Histological Assessment of Adrenergic Cell Distribution 
To determine the localization of adrenergic-derived myocardium, we 
utilized X-gal staining to identify positive cell populations.  At 8-9 months hearts 
and adrenals were excised from male and female mice and frozen sections were 
stained.  Interestingly, the male heart sections showed a robust staining pattern 
in the left heart and especially in the basal regions (Figure 24B).  However, little 
to no positive staining was observed in the female left heart; however staining 
was readily present in the female 9 month adrenal gland (Figure 24A).  At 21 
months all mice were euthanized and hearts and adrenals removed and 
processed as indicated in Materials and Methods section.  By this age no 
staining was observed in the male hearts or cycling female hearts, however, blue 
X-gal+ cells were clearly present in the postmenopausal hearts (Figure 24C-E).  
Staining was observed in the adrenal gland of all 21 month mice (Figure 25).  
Quantification of the X-gal+ pixels shows a significant increase in staining the 
males at 9 months compared to aged matched females (Figure 24F).  
Surprisingly, these X-gal+ pixels were significantly decreased in the males at 21 
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months, still not present in premenopausal females and drastically increased in 
postmenopausal females by 21 months (Figure 24F). 
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Discussion 
The stress-induced cardiomyopathy, Takotsubo syndrome, is 
characterized by predominately affecting postmenopausal women, increased 
circulating catecholamines, and hypo or a-kinesis of the mid and apical left 
ventricle (Cocco and Chu, 2007; Wittstein et al., 2005).  To recapitulate this 
syndrome we increased catecholamine levels by injecting EPI (i.p.) and inducing 
emotional stress by immobilization and observed cardiac function via high-
resolution echocardiography (Shao et al., 2013; Ueyama, 2004).  Additionally, as 
age and menopause are common features of this syndrome, mice were aged 
past nine months and menopause was induced and cardiac function studies 
were repeated.  Lastly, using a β-galactosidase reporter we observed the 
localization of intrinsic adrenergic cells  
While little to no apical ballooning was observed after injection of EPI or 
immobilization stress was observed via high-resolution echocardiography, 
interesting results were found regarding differences between age, sex, and 
menopausal status in response to stress paradigms.  We compared the effects of 
left ventricular function using high-resolution ultrasound before and after stress 
response. 
In parallel with other reported cases of stress response in males versus 
females, male nine month mice had a more robust response to EPI stimulation 
as compared to females (Schouwenberg et al., 2006).  Others have reported a 
larger response in males to adrenergic stimulation, in vivo, isolated heart 
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preparations, as well as skinned myocytes (Gao et al., 2003; Schwertz et al., 
1999; Scott et al., 2007).  Investigation into the mechanism behind the greater 
sensitivity in males revealed a two-fold greater beta-adrenergic receptor density 
in male left ventricular membranes (Vizgirda et al., 2002).  However, the function 
of these receptors has been questioned by many (Hinojosa-Laborde et al., 1999) 
and never been examined in vivo experimentation. 
Premenopausal female patients (less than 65) are known to have better 
outcomes to hypertension, aortic stenosis and hypertrophic cardiomyopathy and 
preserved left ventricular ejection fraction in heart failure (Regitz-Zagrosek et al., 
2010).  However, these statistics change drastically after the age of 65 and 
initiation of menopause (Luczak and Leinwand, 2009).  Consequently, the role of 
estrogen and cardiovascular function has been extensively studied, though few 
studies have investigations have been conducted in vivo (Dubey and Jackson, 
2001; McIntosh et al., 2011; Schaible et al., 1984).  Here we show differences 
between males, cycling and menopausal females when measuring heart rate 
response, stroke volume and cardiac output to EPI stimulation.   
Additionally, our results demonstrate a similar aging pattern observed 
previously, that males have a significant increase in left ventricular end systolic 
and diastolic volume with age (Grandi et al., 1992).  Whereas females show left 
ventricular stiffness exhibited by a drastic decrease in stroke volume over nine 
months of age (Borlaug et al., 2013). 
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Our studies also investigated the effects of an emotional stress paradigm, 
immobilization stress, with regards to gender and menopausal status.  Here we 
show menopausal females have similar response to stress as males with regards 
to heart rate response, stroke volume and cardiac output.  Cycling females have 
a decreased stroke volume as well as cardiac output compared to age matched 
male and menopausal female mice. 
To understand the distribution of adrenergic derived myocardium with 
regards to age, gender, and menopausal status hearts were excised, sectioned, 
and stained for X-gal+ cells.  The young adult mouse (3-8 weeks) was shown to 
have a distinct left sided distribution of intrinsic cardiac adrenergic cells.  This 
characteristic pattern was observed in males at nine months of age, however, 
little to no ICA cells were observed in the myocardium of the cycling female heart 
at nine months.  At 21 months ICA cells were no longer observed in the male 
heart, interestingly though the ICA cells were not observed in the menopausal 
female heart.  One studied examined the rate of myocyte turnover in the aging 
heart, revealing the human male heart loses approximately 1 gram of myocytes 
per year, this is not seen in female hearts (Olivetti et al., 1995). 
Controversial research has been conducted on whether estrogen levels 
regulate adrenergic receptors receptor and expression, especially in the heart.  
One study showed an upregulation of the β-1 adrenergic receptor in menopausal 
rats (Thawornkaiwong et al., 2003).  While others have shown increased beta-
adrenergic responses in male left ventricles, thought to be due to increased 
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calcium influx (McIntosh et al., 2011).  Unfortunately, there has been no research 
conducted in adrenergic receptor sensitivity to estrogen in whole hearts. 
Here we have shown a differential left ventricular response to stressors in 
males and females.  Interestingly, trends toward similar LV responses to stress 
(EPI and IMO) were seen between males and menopausal females as compared 
to age-matched cycling females.  Additionally, a drastic reappearance of intrinsic 
cardiac adrenergic cells were observed and quantified in the menopausal left 
ventricular and apical regions of the heart.  This sudden reappearance may 
account for a higher incidence of takotsubo cardiomyopathies observed in post-
menopausal females due to higher local catecholamine release.  However, future 
studies are necessary to determine if this is the pathogenesis of stress-induced 
cardiomyopathies. 
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Tables 
 
Table 6 Echocardiography results for 9 month male and female mice at 
baseline and after EPI (50 mg/kg, i.p.) 
 
 
Data are represented as mean±SEM. *, p<0.05; **, p<0.01; ***, p<0.001 
 
 
 
 
 
 
Baseline Epinephrine 
  
Males 
n=28 
 
Females 
n=30 
 
p-value 
 
Males 
n=28 
 
Females 
n=30 
 
p-value 
 
Heart Rate (bpm) 
 
  
451.8±7.5 
  
484.5±9.0 
 
0.007*** 
  
526.5±5.0 
  
536.0±5.8 
 
0.2 
End Systolic LV 
Volume (µL) 
 
  
17.0±0.9 
  
12.7±0.7 
 
0.0006*** 
  
12.0±1.0 
  
11.6±0.8 
 
0.8 
End Diastolic LV 
Volume (µL) 
 
  
56.7±1.9 
  
43.3±1.5 
 
<0.0001*** 
  
48.4±2.3 
  
41.5±1.3 
 
0.01* 
Stroke Volume 
(µL) 
 
  
39.7±1.7 
  
30.6±1.2 
 
<0.0001*** 
  
36.4±1.9 
  
29.9±1.1 
 
0.004** 
Ejection Fraction 
(%) 
 
  
69.6±1.4 
  
70.5±1.4 
 
0.7 
  
75.0±1.9 
  
72.2±1.7 
 
0.3 
 
Fractional 
Shortening (%) 
 
  
19.1±1.3 
 
20.1±1.0 
 
0.5 
  
21.1±1.3 
  
19.3±1.2 
 
0.3 
Cardiac Output 
(mL/min) 
 
  
18.1±0.9 
  
14.7±0.6 
 
0.002** 
  
19.2±1.0 
  
16.1±0.6 
 
0.01** 
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Table 7 Echocardiography results for 18 month male, cycling and 
menopausal female mice at baseline and after EPI (50 mg/kg, i.p.) 
 
 
Data are represented as mean±SEM. *, p<0.05; **, p<0.01; ***, p<0.001 
 
 
 
 
 
 
 
Baseline Epinephrine 
  
Males 
n=6 
Cycling 
Females 
n=6 
Menopausal 
Females 
n=12 
 
p-value 
 
Males 
n=6 
Cycling 
Females 
n=6 
Menopausal 
Females 
n=12 
 
p-value 
 
Heart Rate (bpm) 
 
  
436.8±13.9 
  
460.3±18.5 
  
443.1±9.2 
 
0.5 
  
510.6±10.2 
  
557.7±9.3 
  
537.1±8.1 
 
0.02* 
End Systolic LV 
Volume (µL) 
 
  
27.3±2.6 
  
13.5±2.6 
  
23.1±2.4 
 
0.01* 
  
11.2±2.2 
  
7.1±0.8 
  
13.6±2.5 
 
0.2 
End Diastolic LV 
Volume (µL) 
 
  
66.3±4.8 
  
46.2±1.5 
  
58.6±2.8 
 
0.004** 
  
57.0±3.1 
  
37.9±3.0 
  
49.1±3.5 
 
0.01* 
Stroke Volume 
(µL) 
 
  
39.0±3.2 
  
32.7±1.3 
  
35.5±1.7 
 
0.2 
  
45.8±3.0 
  
30.8±2.5 
  
35.6±2.1 
 
0.004** 
Ejection Fraction 
(%) 
 
  
59.5±2.9 
  
71.8±4.6 
  
61.5±2.6 
 
0.06 
  
81.1±3.2 
  
82.2±1.6 
  
74.1±3.0 
 
0.1 
Fractional 
Shortening (%) 
 
  
14.6±2.9 
 
27.0±3.6 
  
20.7±2.4 
 
0.05* 
  
24.6±3.1 
  
29.2±1.7 
  
25.4±2.5 
 
0.5 
Cardiac Output 
(mL/min) 
 
  
16.9±1.0 
  
15.1±0.9 
  
15.7±0.8 
 
0.5 
  
23.3±1.4 
  
17.2±1.5 
  
19.0±1.0 
 
0.02* 
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Table 8 Echocardiography results for 21 month male, cycling and 
menopausal female mice at baseline and immobilization stress 
 
 
Data are represented as mean±SEM. *, p<0.05; **, p<0.01; ***, p<0.001 
   
 
Baseline Immobilization 
  
Males 
n=6 
Cycling 
Females 
n=6 
Menopausal 
Females 
n=11 
 
p-value 
 
Males 
n=6 
Cycling 
Females 
n=6 
Menopausal 
Females 
n=11 
 
p-value 
 
Heart Rate (bpm) 
 
  
465.5±33.0 
  
398.4±8.9 
  
416.8±11.0 
 
0.07 
  
657.7±15.3 
  
692.5±7.5 
  
687.0±5.8 
 
0.05* 
End Systolic LV 
Volume (µL) 
 
  
44.4±7.6 
  
34.6±6.5 
  
36.1±4.7 
 
0.5 
  
5.1±2.9 
  
1.1±0.4 
  
2.1±0.4 
 
0.2 
End Diastolic LV 
Volume (µL) 
 
  
85.5±10.1 
  
64.2±9.7 
  
71.8±5.5 
 
0.2 
  
37.9±4.0 
  
24.0±2.8 
  
33.6±2.5 
 
0.03* 
Stroke Volume 
(µL) 
 
  
41.1±4.1 
  
29.6±4.3 
  
35.7±3.3 
 
0.2 
  
32.7±2.3 
  
22.9±2.6 
  
31.5±2.3 
 
0.04* 
Ejection Fraction 
(%) 
 
  
51.0±6.6 
  
47.8±4.1 
  
51.9±5.1 
 
0.9 
  
88.6±5.2 
  
95.6±1.2 
  
94.1±0.9 
 
0.2 
Fractional 
Shortening (%) 
 
  
26.8±4.7 
 
24.0±2.5 
  
27.2±3.3 
 
0.8 
  
61.6±5.9 
  
71.8±3.2 
  
68.6±2.2 
 
0.2 
Cardiac Output 
(mL/min) 
 
  
18.8±1.6 
  
11.6±1.6 
  
14.9±1.4 
 
0.03* 
  
21.5±1.6 
  
15.9±1.8 
  
21.7±1.6 
 
0.06 
 
LV Mass (mg) 
 
  
201.3±17.1 
  
194.0±19.9 
  
175.1±10.7 
 
0.4 
  
198.4±27.4 
  
155.4±21.9 
  
158.7±9.0 
 
0.2 
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Figures 
 
 
 
Figure 17 Schematic of mouse model. 
(A) PnmtCre/Cre and ROSA26βgal/βgal homozygous mice mating scheme and 
resulting heterozygous offspring genotypes.  (B) Recombination of Rosa26 
reporter mice and Pnmt-Cre mice results in robust expression of LacZ gene. 
 
  
PnmtCre/Cre  ROSA26βgal/βgal  
ROSA26+/βgal Pnmt+/Cre 
A B 
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Figure 18 EPI injection of males and pre-menopausal 9 month old mice. 
(A) Heart Rate (B) End Systolic Volume (C) End Diastolic Volume (D) Stroke 
Volume (E) Cardiac Output B-mode ultrasound analysis of 9 month old male and 
female mice before and after EPI challenge.  (F) Percent change calculated in 
response to EPI in male and female mice.  n=28 males and 30 females.  Data 
represented as mean ± SEM.  *, p>0.05; **, p>0.01; ***p>0.001. 
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Figure 19 EPI injection of males, pre and post-menopausal females at 18 
months. 
(A) Heart Rate (B) End Systolic Volume (C) End Diastolic Volume (D) Stroke 
Volume (E) Cardiac Output B-mode ultrasound analysis of 18 month old male 
and female (cycling and menopausal) mice before and after EPI challenge.  (F) 
Percent change calculated in response to EPI in male and female (cycling and 
menopausal) mice.  n=6 males, 6 cycling females and 12 menopausal females.  
Data represented as mean ± SEM.  *, p>0.05; **, p>0.01. 
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Figure 20 Effects of age and EPI in males. 
(A) Heart Rate (B) End Systolic Volume (C) End Diastolic Volume (D) Stroke 
Volume (E) Cardiac Output B-mode ultrasound analysis of 9 and 18 month old 
male mice before and after EPI challenge.  (F) Percent change calculated from 9 
months to 18 months in response to EPI.  n=28 at 9 months and 6 at 18 months. 
Data represented as mean ± SEM.  *, p>0.05; **, p>0.01; ***p>0.001 
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Figure 21 Effects of age and EPI in males. 
A) Heart Rate (B) End Systolic Volume (C) End Diastolic Volume (D) Stroke 
Volume (E) Cardiac Output B-mode ultrasound analysis of 9 and 18 month old 
male mice before and after EPI challenge.  (F) Percent change calculated from 9 
months to 18 months in response to EPI.  n=30 at 9 months and 6 at 18 months. 
Data represented as mean ± SEM.  *, p>0.05; **, p>0.01. 
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Figure 22 Immobilization stress on males, pre and post-menopausal 
females at 21 months old. 
(A) Heart Rate (B) End Systolic Volume (C) End Diastolic Volume (D) Stroke 
Volume (E) Cardiac Output B-mode ultrasound analysis of 21 month old male 
and female (cycling and menopausal) mice before and after immobilization 
stress.  (F) Percent change calculated in response to immobilization in male and 
female (cycling and menopausal) mice.  n=6 males, 6 cycling females and 12 
menopausal females.  Data represented as mean ± SEM.  *, p>0.05. 
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Figure 23 Corticosterone levels of males pre and post-menopausal females 
compared to unstressed controls. 
Plasma corticosterone after immobilization stress in 21 month males, 
menopausal and cycling females compared to unstressed controls.  n=6 
males,11 menopausal females, 6 cycling females, and 4 unstressed controls.  
Data represented as mean ± SEM.  *, p>0.05. 
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Figure 24 Representative X-gal staining of 9 month males and females and 
21 month males and pre and post-menopausal females. 
Representative x-gal staining of (A) female 9 month heart section (B) male 9 
month heart section (C) 21 month cycling female heart section (D) 21 month 
male heart section (E) 21 month menopausal female heart section.  (F) 
Quantification of x-gal+ blue pixels.  n=7 males at 9 months, 5 females at 9 
months, 5 males at 21 months, 4 cycling females at 21 months, 4 menopausal 
females at 21 months.  Data represented as mean ± SEM.  *, p>0.05. 
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Figure 25 Representative adrenal sections from 21 month mice. 
Representative x-gal staining of (A) male 21 month adrenal section (B) 
menopausal female 21 month adrenal section (C) cycling female 21 month 
adrenal section.   
 
  
Male Cycling FemaleMenopausal Female
A CB
122 
 
List of References 
Baker, C., Katsandris, Rebekah, Van, Chaunhi and Steven Ebert (2014). 
Adrenaline and Stress-Induced Cardiomyopathies: Three competing hypotheses 
for mechanism(s) of action. In Adrenaline: Production, Role in Disease and 
Stress, Effects on the Mind and Body, A. Bennun, ed. (New York: Nova Science 
Publishers), pp. 81-116. 
 
Borlaug, B.A., Redfield, M.M., Melenovsky, V., Kane, G.C., Karon, B.L., 
Jacobsen, S.J., and Rodeheffer, R.J. (2013). Longitudinal changes in left 
ventricular stiffness: a community-based study. Circulation Heart failure 6, 944-
952. 
 
Cleland, J.G., Swedberg, K., Follath, F., Komajda, M., Cohen-Solal, A., Aguilar, 
J.C., Dietz, R., Gavazzi, A., Hobbs, R., Korewicki, J., et al. (2003). The 
EuroHeart Failure survey programme-- a survey on the quality of care among 
patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. 
European heart journal 24, 442-463. 
 
Cocco, G., and Chu, D. (2007). Stress-induced cardiomyopathy: A review. 
European journal of internal medicine 18, 369-379. 
 
Du, X.J. (2004). Gender modulates cardiac phenotype development in 
genetically modified mice. Cardiovascular research 63, 510-519. 
 
Dubey, R.K., and Jackson, E.K. (2001). Cardiovascular protective effects of 
17beta-estradiol metabolites. J Appl Physiol (1985) 91, 1868-1883. 
 
Gao, X.M., Agrotis, A., Autelitano, D.J., Percy, E., Woodcock, E.A., Jennings, 
G.L., Dart, A.M., and Du, X.J. (2003). Sex hormones and cardiomyopathic 
phenotype induced by cardiac beta 2-adrenergic receptor overexpression. 
Endocrinology 144, 4097-4105. 
 
Grandi, A.M., Venco, A., Barzizza, F., Scalise, F., Pantaleo, P., and Finardi, G. 
(1992). Influence of age and sex on left ventricular anatomy and function in 
normals. Cardiology 81, 8-13. 
 
H. Sato, H.T., K. Dote, T. Uchida, M. Ishihara (1990). Tako-tsubo-like left 
ventricular dysfunction due to multivessel coronary spasm (Kagakuhyoronsha 
Publishing Co., Tokyo), pp. 56-64. 
 
Hinojosa-Laborde, C., Chapa, I., Lange, D., and Haywood, J.R. (1999). Gender 
differences in sympathetic nervous system regulation. Clinical and experimental 
pharmacology & physiology 26, 122-126. 
123 
 
 
Hogg, K., Swedberg, K., and McMurray, J. (2004). Heart failure with preserved 
left ventricular systolic function; epidemiology, clinical characteristics, and 
prognosis. Journal of the American College of Cardiology 43, 317-327. 
 
Hoyer, P.B., and Sipes, I.G. (2007). Development of an animal model for 
ovotoxicity using 4-vinylcyclohexene: a case study. Birth defects research Part B, 
Developmental and reproductive toxicology 80, 113-125. 
 
Kume, T., Kawamoto, T., Okura, H., Toyota, E., Neishi, Y., Watanabe, N., 
Hayashida, A., Okahashi, N., Yoshimura, Y., Saito, K., et al. (2008). Local 
release of catecholamines from the hearts of patients with tako-tsubo-like left 
ventricular dysfunction. Circulation journal : official journal of the Japanese 
Circulation Society 72, 106-108. 
 
Luczak, E.D., and Leinwand, L.A. (2009). Sex-based cardiac physiology. Annual 
review of physiology 71, 1-18. 
 
McIntosh, V.J., Chandrasekera, P.C., and Lasley, R.D. (2011). Sex differences 
and the effects of ovariectomy on the beta-adrenergic contractile response. 
American journal of physiology Heart and circulatory physiology 301, H1127-
1134. 
 
Olivetti, G., Giordano, G., Corradi, D., Melissari, M., Lagrasta, C., Gambert, S.R., 
and Anversa, P. (1995). Gender differences and aging: effects on the human 
heart. Journal of the American College of Cardiology 26, 1068-1079. 
 
Osuala, K., Telusma, K., Khan, S.M., Wu, S., Shah, M., Baker, C., Alam, S., 
Abukenda, I., Fuentes, A., Seifein, H.B., et al. (2011). Distinctive left-sided 
distribution of adrenergic-derived cells in the adult mouse heart. PloS one 6, 
e22811. 
 
Regitz-Zagrosek, V., Brokat, S., and Tschope, C. (2007). Role of gender in heart 
failure with normal left ventricular ejection fraction. Progress in cardiovascular 
diseases 49, 241-251. 
 
Regitz-Zagrosek, V., Oertelt-Prigione, S., Seeland, U., and Hetzer, R. (2010). 
Sex and gender differences in myocardial hypertrophy and heart failure. 
Circulation journal : official journal of the Japanese Circulation Society 74, 1265-
1273. 
 
Schaible, T.F., Malhotra, A., Ciambrone, G., and Scheuer, J. (1984). The effects 
of gonadectomy on left ventricular function and cardiac contractile proteins in 
male and female rats. Circulation research 54, 38-49. 
124 
 
 
Schouwenberg, B.J., Rietjens, S.J., Smits, P., and de Galan, B.E. (2006). Effect 
of sex on the cardiovascular response to adrenaline in humans. Journal of 
cardiovascular pharmacology 47, 155-157. 
 
Schwertz, D.W., Vizgirda, V., Solaro, R.J., Piano, M.R., and Ryjewski, C. (1999). 
Sexual dimorphism in rat left atrial function and response to adrenergic 
stimulation. Molecular and cellular biochemistry 200, 143-153. 
 
Scott, J.M., Esch, B.T., Haykowsky, M.J., Isserow, S., Koehle, M.S., Hughes, 
B.G., Zbogar, D., Bredin, S.S., McKenzie, D.C., and Warburton, D.E. (2007). Sex 
differences in left ventricular function and beta-receptor responsiveness following 
prolonged strenuous exercise. J Appl Physiol (1985) 102, 681-687. 
 
Shao, Y., Redfors, B., Stahlman, M., Tang, M.S., Miljanovic, A., Mollmann, H., 
Troidl, C., Szardien, S., Hamm, C., Nef, H., et al. (2013). A mouse model reveals 
an important role for catecholamine-induced lipotoxicity in the pathogenesis of 
stress-induced cardiomyopathy. Eur J Heart Fail 15, 9-22. 
 
Thawornkaiwong, A., Preawnim, S., and Wattanapermpool, J. (2003). 
Upregulation of beta 1-adrenergic receptors in ovariectomized rat hearts. Life 
sciences 72, 1813-1824. 
 
Ueyama, T. (2004). Emotional stress-induced Tako-tsubo cardiomyopathy: 
animal model and molecular mechanism. Annals of the New York Academy of 
Sciences 1018, 437-444. 
 
Vizgirda, V.M., Wahler, G.M., Sondgeroth, K.L., Ziolo, M.T., and Schwertz, D.W. 
(2002). Mechanisms of sex differences in rat cardiac myocyte response to beta-
adrenergic stimulation. American journal of physiology Heart and circulatory 
physiology 282, H256-263. 
 
Wittstein, I.S., Thiemann, D.R., Lima, J.A., Baughman, K.L., Schulman, S.P., 
Gerstenblith, G., Wu, K.C., Rade, J.J., Bivalacqua, T.J., and Champion, H.C. 
(2005). Neurohumoral features of myocardial stunning due to sudden emotional 
stress. The New England journal of medicine 352, 539-548. 
 
Yoshida, T., Hibino, T., Kako, N., Murai, S., Oguri, M., Kato, K., Yajima, K., Ohte, 
N., Yokoi, K., and Kimura, G. (2007). A pathophysiologic study of tako-tsubo 
cardiomyopathy with F-18 fluorodeoxyglucose positron emission tomography. 
Eur Heart J 28, 2598-2604. 
 
 
125 
 
CHAPTER FIVE: CONCLUSIONS 
Cardiovascular disease is the primary cause of death in adults in the 
United States and accounts for 26.6 percent of all infants that die of congenital 
birth defects.  Adrenergic hormones are known regulators of cardiovascular 
function in both embryos and adults, they are mediators of stress responses and 
have profound stimulatory effects on cardiovascular function.  My thesis 
addressed critical questions regarding the involvement of catecholamines in the 
embryonic heart and the role of catecholamines in cardiac function in young and 
aged male and female hearts.  I explored the roles of adrenergic hormones in the 
development of the embryonic conduction system as well as showed a link 
between adrenergic-hormones and mitochondrial functional maturation during 
embryogenesis.  Further, I performed longitudinal high-resolution 
echocardiography on male and female mice incorporating menopausal status as 
a variable and tested the effect of stress on heart function by the injection of 
epinephrine and immobilization. 
The major conclusions found from the second chapter of work presented 
here include: 
1. Adrenergic deficiency leads to decreased connexin 43 in embryonic 
(E)10.5 atrioventricular junctional regions but not E9.5 mouse 
hearts 
2. Atrioventricular conduction is significantly slower in adrenergic-
deficient hearts 
3. Arrhythmic activity is significantly induced in adrenergic-deficient 
hearts compared with adrenergic-competent controls 
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These findings indicate that adrenergic hormones are critical for the 
development of the cardiac conduction system.  Disruption of this key signaling 
pathway either by genetic anomalies or pharmacological intervention could result 
in permanent cardiovascular conduction defects.  To further understand the 
nature of the atrioventricular delay observed in the adrenergic-deficient hearts 
and the association, if any, of decreased Cx43 the use of CRISPR (clustered 
regularly interspaced short palindromic repeats)/Cas9 modeling could provide a 
powerful genetic tool (Mali et al., 2013).  The Dbh gene could easily be disrupted 
in a Cx43 overexpression mouse model (Ewart et al., 1997) using these new 
technologies and creating a novel transgenic colony.  Again, utilizing the 
microelectrode arrays we would determine if the loss of adrenergic hormones 
slow the propagation of the conduction system from the atrium to the ventricle 
through the A-V region in this unique model.  Further, the characterization of 
Cx43 protein levels at E9.5-E11.5 in the adrenergic-deficient embryonic hearts 
will prove incredibly informative.  While, we do see a decrease in 
immunofluorescence staining of Cx43, a direct measure of protein content would 
elucidate if there is true down regulation of this important gap junction protein in 
an adrenergic-deficient state.  Lastly, as mentioned previously the gene and 
protein levels of connexin 45, 40, and 37.5 would provide information if there is 
any compensation by other gap junction proteins that are known to be expressed 
in the early heart. 
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The major conclusions found from the third chapter of work presented 
here include: 
1. Adrenergic hormones are necessary to maintain sufficient 
ATP/ADP ratios 
2. Extracellular acidification rates and oxygen consumption rates are 
significantly decreased in adrenergic-deficient hearts during late 
periods of embryonic development 
3. Metabolic steady-state substrate levels are unaffected due to the 
loss of adrenergic hormones 
4. Mitochondrial biogenesis genes are unaffected due to the loss of 
adrenergic hormones 
5. Mitochondrial membrane potential is similar between adrenergic-
deficient and competent embryonic hearts 
6. Adrenergic hormones influence embryonic cardiac mitochondrial 
morphology 
The loss of adrenergic hormones results in a severe energy deficiency in 
the developing embryonic heart during the critical transition from embryonic to 
fetal development.  This period coincides with the “embryonic shift” from mainly 
glycolytic mechanisms to oxidative phosphorylation energy production.  Thus 
adrenergic hormones could be a major driving factor for this shift in energy 
production modalities.   
Potential exploration into the involvement of catecholamines and the 
mechanism(s) that drive this shift will provide knowledge of the basic 
organization of the energy metabolism system within mammalian development.  
Possible explanations for the necessity of adrenergic hormones in up regulation 
mitochondrial activity could involve the assembly of the supercomplexes 
composed of the electron transport complex.  While the machinery of each 
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complex (I-V) is maternally inherited, and present from fertilization, the 
organization of these individual complexes is a multifaceted and understudied 
field.  It could conceivably be the presence and PKA stimulation driven by 
adrenergic hormones that facilitates the joining of the complexes into a functional 
supercomplex. 
Additionally, a prominent feature of the work discussed in this chapter 
includes irregularly shaped and elongated mitochondria.  The mechanistic 
rationale behind this intriguing finding is currently unknown, however, future 
studies involve the examination of mitochondrial fission and fusion genes.  The 
fission genes include dynamin-related protein 1 (Drp1) and fission 1 (Fis1) and 
the mitochondrial fusion genes localized to the outer membrane are mitofusin 1 
(Mfn1) and mitofusion 2 (Mfn2).  Additionally, the inner membrane fusion gene is 
optic atrophy 1 (Opa1) (Knott et al., 2008).  While the gene expression levels of 
these fission/fusion regulators may be informative in determining a causal nature 
of the mitochondrial morphological abnormalities observed in the adrenergic-
deficient embryonic heart, protein levels, as well of phosphorylation status could 
be of greater enlightenment.  Drp1 for example is known to be regulated by PKA 
phosphorylation on residue S656 in rats.  This phosphorylation negatively 
regulates Drp1 and thus inhibits fission (Chang and Blackstone, 2007).  Similarly, 
Mfn2 was discovered to contain a PKA phosphorylation site, S442 in rats.  While 
the rate of fusion was not examined in the phospho-deficient of phospho-mimetic 
states the effects of vascular smooth muscle cell proliferation as a result of Mfn2 
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was found to be highly correlated with the phosphorylation status (Zhou et al., 
2010). 
An interesting feature of the Dbh-/- embryos is the subviability seen in the 
maternal heterozygous as compared to the complete embryonic lethality 
observed in the maternal homozygous state.  It has been hypothesized the 
explanation for this phenomenon is due to maternal adrenergic hormonal 
influence (Thomas et al., 1995).  However, mitochondria and the mitochondrial 
genome, containing any mutations, are inherited solely from the maternal egg.  
Within all mitochondrial dysfunction models a threshold effect occurs wherein the 
mutational load reaches a point the phenotype presents itself and under this level 
the phenotype is muted.  A potential future direction would be to perform a 
microinjection of eggs that have undergone in vitro fertilization from heterozygous 
(Dbh+/-) dam and sire into a homozygous (Dbh-/-) pseudopregnant female.  Within 
this investigation one could test if the lack of maternal hormones cause the early 
embryonic lethality or if the incomplete penetrance of the mitochondrial 
mutational load inherited from a heterozygous mother is the explanation for the 
subviability  
The major conclusions found from the fourth chapter of work presented 
here include: 
1. Differential left ventricular response to epinephrine and 
immobilization stressors in males versus females 
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2. Similar left ventricular responses to epinephrine and immobilization 
stressors were seen between males and menopausal females as 
compared to age-matched cycling females 
3. A drastic reappearance of intrinsic cardiac adrenergic cells were 
observed and quantified in the menopausal left ventricular and 
apical regions of the heart 
The differential responses to stressors in combination with the pattern of 
intrinsic adrenergic myocardium could provide useful information for the clinical 
syndrome known as takotsubo cardiomyopathy.  The creation of a mouse model 
for this stress induced cardiomyopathy yields a powerful tool for understanding 
the currently undefined pathophysiology.  Much work has been conducted 
regarding the design of an animal model, with little understanding of the 
mechanisms driving this syndrome (Shao et al., 2013a; Shao et al., 2013b). 
The modes of stress induction in the mouse model presented here, in 
addition to menopausal induction, provide a scenario quite similar to the human 
condition.  However, a potential pitfall in utilizing the mouse as a surrogate for the 
human cardiovascular system is the over stimulated nature of the mouse in a 
basal state.  The conscious mouse heart rate ranges from 500-650 beats per 
minute were as the average human heart rate is 60-100 beats per minute.  The 
mouse is already in a “stressed” state and external stimuli (i.e. epinephrine and 
or restraint) may not have the complete desired outcome.  For this reason the 
use of larger animal models that are more akin to human cardiovascular function, 
such as rabbits, dogs, or cats, may be a suitable alternative to the use of rodents. 
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The mouse model utilized here, Pnmt+/Cre ROSA26+/βgal, provided the 
opportunity to investigate the intrinsic adrenergic myocardium over time and in 
response to menopausal status.  However, the LacZ staining observed here is a 
historical representation of cells that are capable of producing stress hormones.  
Within this study we have not measured the production of epinephrine or 
norepinephrine in the heart in response to menopause or stress.  A potential 
experiment to test the levels of NE/EPI produced would involve culturing the 
area(s) most heavily stained (i.e. the left ventricle and atrium) in the aged and 
menopausal hearts as compared to controls.  While the use of restraint stress 
would not be feasible, provocation with isoproterenol could induce increased 
beating activity in the cultured myocytes and allow for quantification of the NE 
and EPI that is being produced in response to stres.  While these experiments 
could be informative, they would require a new cohort of mice and reproduction 
of the colony. 
Alternatively, the current samples available from the study performed here 
can be sectioned and stained directly for norepinephrine, epinephrine or other 
markers such as Dbh and Pnmt.  While quantification is certainly a challenge with 
immunofluorescence, differences can be readily observed, especially if the 
intensity is electronically quantified using 3D software such as Volocity® (Perkin 
Elmer).  By employing this method both functional data, via echocardiography, 
and biochemical depiction of the levels of adrenergic hormones present in the 
areas that stain heavily with LacZ. 
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The work performed here demonstrates the importance of adrenergic 
hormones in both the developing cardiovascular system as well as the adult 
heart.  Additionally, this work provides a unique perspective on the effect 
adrenergic hormones have on cardiovascular function, heart failure, and sudden 
cardiac death.  These adult cardiac disease states are often capable of 
prevention through manipulation of life style, congenital malformations however, 
presents at a stage so early in the pregnancy that most women do not realize 
they are even pregnant and have the ability to alter the course of gestation.  
Surgical intervention is commonly the only treatment option available to correct 
these congenital heart defects.  Thus understanding the typical embryogenesis 
and organogenesis patterns and the downstream implications these hormones 
have is of critical importance to developing new treatment options and potentially 
prevention of congenital heart disease.   
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